<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AES</journal-id>
<journal-id journal-id-type="hwp">spaes</journal-id>
<journal-id journal-id-type="nlm-ta">Aesthet Surg J</journal-id>
<journal-title>Aesthetic Surgery Journal</journal-title>
<issn pub-type="ppub">1090-820X</issn>
<issn pub-type="epub">1527-330X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1090820X13493638</article-id>
<article-id pub-id-type="publisher-id">10.1177_1090820X13493638</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cosmetic Medicine</subject>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>80</subject>
<subject>90</subject>
<subject>880</subject>
<subject>881</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Complications Following Injection of Soft-Tissue Fillers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ozturk</surname><given-names>Cemile Nurdan</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Yumeng</given-names></name>
<degrees>BS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Tung</surname><given-names>Rebecca</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Parker</surname><given-names>Lydia</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Piliang</surname><given-names>Melissa Peck</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zins</surname><given-names>James E.</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-1090820X13493638">Dr Ozturk is an Aesthetic Surgery Fellow at the Cleveland Clinic, Cleveland, Ohio</aff>
<aff id="aff2-1090820X13493638">Dr Zins is Chairman of the Department of Plastic Surgery at the Cleveland Clinic, Cleveland, Ohio</aff>
<aff id="aff3-1090820X13493638">Dr Piliang is a staff physician in the Departments of Dermatology and Anatomic Pathology at the Cleveland Clinic, Cleveland, Ohio</aff>
<aff id="aff4-1090820X13493638">Ms Li is a medical student at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio</aff>
<aff id="aff5-1090820X13493638">Dr Tung is Chairman of the Division of Dermatology at Loyola University, Stritch School of Medicine, Maywood, Illinois</aff>
<aff id="aff6-1090820X13493638">Dr Parker is a Clinical Instructor in the Department of Dermatology at Case Western Reserve University, School of Medicine, Cleveland, Ohio</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1090820X13493638">Dr James E. Zins, Department of Plastic Surgery, Cleveland Clinic, 9500 Euclid Ave, Desk A60, Cleveland, OH 44195, USA. Email: <email>zinsj@ccf.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>6</issue>
<fpage>862</fpage>
<lpage>877</lpage>
<history>
<date date-type="accepted">
<day>26</day>
<month>11</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2013 The American Society for Aesthetic Plastic Surgery, Inc.</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">American Society for Aesthetic Plastic Surgery, Inc.</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1090820X13493638">
<title>Background:</title>
<p>Soft-tissue filler injection is a very common procedure in the United States. Although the safety profile is favorable, adverse events (AE) can occur, ranging from mild to severe in intensity.</p>
</sec>
<sec id="section2-1090820X13493638">
<title>Objectives:</title>
<p>The authors performed a literature search to identify the facial sites most prone to severe complications. They review the course of these complications and discuss preventive measures.</p>
</sec>
<sec id="section3-1090820X13493638">
<title>Methods:</title>
<p>The National Library of Medicine, the Cochrane Library, and Ovid MEDLINE were searched, and relevant articles (published through August 2012) were retrieved based on prespecified inclusion criteria. The complications reviewed were limited to “severe” events, such as soft-tissue necrosis, filler embolization, visual impairment, and anaphylaxis. The filler materials included were those approved by the US Food and Drug Administration at the time of this study.</p>
</sec>
<sec id="section4-1090820X13493638">
<title>Results:</title>
<p>Forty-one articles, representing 61 patients with severe complications, were identified. Data collected from these case reports included filler type, injection site, complication site, symptom interval, symptom of complication, time to therapy, modality of treatment, and outcome. The most common injection site for necrosis was the nose (33.3%), followed by the nasolabial fold (31.2%). Blindness was most often associated with injection of the glabella (50%). An estimated incidence of 0.0001% for developing a severe complication was calculated by reviewing society-based filler data and case reports within same time period.</p>
</sec>
<sec id="section5-1090820X13493638">
<title>Conclusions:</title>
<p>Although soft-tissue fillers are a popular choice for minimally invasive rejuvenation of the face, physicians should be aware of the serious potential adverse effects, recognize their presentations, and have appropriate treatments readily available.</p>
</sec>
</abstract>
<kwd-group>
<kwd>filler</kwd>
<kwd>injectable</kwd>
<kwd>complication</kwd>
<kwd>blindness</kwd>
<kwd>necrosis</kwd>
<kwd>cosmetic medicine</kwd>
<kwd>literature review</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The use of soft-tissue fillers for cosmetic purposes has increased dramatically in recent years. According to the 2012 statistics published by the American Society for Aesthetic Plastic Surgery (ASAPS), fillers are now the second most common minimally invasive procedure performed among plastic surgeons, behind botulinum toxin injections.<sup><xref ref-type="bibr" rid="bibr1-1090820X13493638">1</xref></sup> The trend is similar in dermatology practice. Data from the American Society for Dermatologic Surgery (ASDS) demonstrate that injectables are also the second most common minimally invasive procedure performed by dermatologists (also following botulinum toxin).<sup><xref ref-type="bibr" rid="bibr2-1090820X13493638">2</xref></sup> The popularity of fillers is attributable to their ease of application, significant beneficial effect on appearance, and low rate of complications.</p>
<p>Although soft-tissue fillers have a very favorable safety profile, adverse events (AE) can occur. Minimal and self-limited complications are relatively common and perhaps would be more appropriately termed <italic>adverse sequelae</italic> rather than true complications. Such events include ecchymosis, swelling, and erythema. More significant yet self-limited complications also have occurred, including overcorrection, irregularities, filler visibility, Tyndall effect, and granuloma formation. Complications of greater severity also have been reported, such as visual impairment, skin necrosis, and anaphylaxis. The goal of the present review is to highlight the more serious complications, identify the areas and techniques most prone to complications, suggest means for minimizing complications, and discuss effective methods of treatment.</p>
<sec id="section6-1090820X13493638" sec-type="methods">
<title>Methods</title>
<p>A literature search was performed to gather information on severe complications following injection of soft-tissue fillers from reports published through August 2012. The databases of the National Library of Medicine (PubMed), the Cochrane Library, and Ovid MEDLINE were searched using the following Boolean string: (anaphylaxis OR blindness OR necrosis OR embolization OR scar OR complication) AND (filler OR injectable). Additional searching was done using the phrases <italic>soft-tissue filler complications, dermal filler complications</italic>, and <italic>injectable complications</italic>. The references cited in selected articles also were reviewed to potentially identify additional reports that matched the criteria. The search was limited to the English-language literature and to the head and neck region.</p>
<p>Reports of “severe” complications following use of injectables were selected for this review; these included soft-tissue necrosis, filler embolization resulting in impending necrosis, blindness, partial loss of vision, transient loss of vision, and anaphylaxis. Cases of visual impairment with concomitant necrosis were counted only once, in the vision loss subgroup. The only filler materials included were those that had been approved by the US Food and Drug Administration (FDA) at the time of the review. These materials were collagen, hyaluronic acid (HA), polymethylmethacrylate (PMMA) suspended in collagen, calcium hydroxylapatite (CaHa), poly-L-lactic acid (PLLA), and injectable dermal matrix. Autologous fat, liquid silicone, and other non-FDA-approved substances were excluded.</p>
</sec>
<sec id="section7-1090820X13493638" sec-type="results">
<title>Results</title>
<p>A total of 41 reports representing 61 patients with severe complications were identified. A summary of the cases, therapies, and outcomes is presented in <xref ref-type="table" rid="table1-1090820X13493638">Table 1</xref>. The complications were classified into 3 groups: (1) soft-tissue necrosis or impending necrosis as a result of filler embolization, (2) visual impairment, and (3) anaphylaxis. <xref ref-type="fig" rid="fig1-1090820X13493638">Figure 1</xref> shows the distribution of complications by injection site. Of the 61 cases, the injection site most commonly associated with complications was the nose (32.8%; n = 20), followed by the glabella (26.2%; n = 16) and the nasolabial fold (NLF) (26.2%; n = 16). In 4 cases, the injection site was not specified.<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref>,<xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref></sup> The distribution of complications according to filler type is shown in <xref ref-type="fig" rid="fig2-1090820X13493638">Figure 2</xref>. Hyaluronic acid was the most common filler implicated in necrotic complications, and collagen was the most common filler resulting in visual impairment. Filler type was not reported for 2 cases.<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref>,<xref ref-type="bibr" rid="bibr6-1090820X13493638">6</xref></sup> One case of anaphylactic shock occurred after the eighth injection session of PMMA.<sup><xref ref-type="bibr" rid="bibr7-1090820X13493638">7</xref></sup> However, neither the specific clinical presentation nor the outcome was described.</p>
<table-wrap id="table1-1090820X13493638" position="float">
<label>Table 1.</label>
<caption><p>Literature Summary: Reports of Severe Complications After Use of Injectable Fillers</p></caption>
<graphic alternate-form-of="table1-1090820X13493638" xlink:href="10.1177_1090820X13493638-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Reference and No. of Cases</th>
<th align="center">Complication</th>
<th align="center">Type of Filler</th>
<th align="center">Injection Site</th>
<th align="center">Symptom Interval, Complaints, Location</th>
<th align="center">Time to Therapy, Treatment Utilized</th>
<th align="center">Outcome</th>
<th align="center">Injecting Physician</th>
<th align="center">Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanke et al, 1991<sup><xref ref-type="bibr" rid="bibr29-1090820X13493638">29</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>Collagen</td>
<td>Glabella</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Monheit, 1998<sup><xref ref-type="bibr" rid="bibr12-1090820X13493638">12</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>Collagen</td>
<td>Nose</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Schanz et al, 2002<sup><xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Glabella</td>
<td>Minutes: reticular pattern at injection site and nose; no pain
<break/>10 days: ulceration at injection site, glabella, and nose</td>
<td>Immediate: low-
<break/>molecular-weight heparin 5000 IE daily (1 wk)</td>
<td>Complete recovery</td>
<td>Dermatologist</td>
<td>Germany</td>
</tr>
<tr>
<td>Friedman et al, 2002<sup><xref ref-type="bibr" rid="bibr24-1090820X13493638">24</xref></sup>
<break/>2 cases</td>
<td>Necrosis</td>
<td>HA</td>
<td>Glabella</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Lowe, 2003<sup><xref ref-type="bibr" rid="bibr33-1090820X13493638">33</xref></sup>
<break/>1 case</td>
<td>Impending necrosis</td>
<td>HA</td>
<td>Lip</td>
<td>Venous occlusion; persistent edema at injection site</td>
<td>NR</td>
<td>NR</td>
<td>Dermatologist</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Bellman, 2006<sup><xref ref-type="bibr" rid="bibr19-1090820X13493638">19</xref></sup>
<break/>1 case</td>
<td>Impending necrosis</td>
<td>HA</td>
<td>NLF</td>
<td>Immediate: bruising; edema at injection site
<break/>2 days: sensitivity; pustules; reticulated bruising; edema at injection site and nasal tip</td>
<td>2 days: dynacin 100 mg PO and prednisone 20 mg PO
<break/>4 days: hydrogen peroxide, mupirocin ointment, and warm compress</td>
<td>Complete recovery</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Narins et al, 2006<sup><xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Lip</td>
<td>Immediate: bleeding and bruising
<break/>Later: necrosis of left lower lip</td>
<td>2 weeks: PO corticosteroid and antibiotics; secondary intention</td>
<td>Complete recovery</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Steinsapir and Steinsapir, 2006<sup><xref ref-type="bibr" rid="bibr25-1090820X13493638">25</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Glabella</td>
<td>NR</td>
<td>NR</td>
<td>Scarring</td>
<td>Ophthalmologist</td>
<td>United States</td>
</tr>
<tr>
<td>Gladstone and Cohen, 2007<sup><xref ref-type="bibr" rid="bibr26-1090820X13493638">26</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Glabella</td>
<td>Necrosis at forehead</td>
<td>NR</td>
<td>NR</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Hirsch et al, 2007<sup><xref ref-type="bibr" rid="bibr21-1090820X13493638">21</xref></sup>
<break/>1 case</td>
<td>Impending necrosis</td>
<td>HA</td>
<td>NLF</td>
<td>2 days: pain and erythema at injection site</td>
<td>2 days: aspirin 325 mg, nitroglycerin paste, and warm compress
<break/>3 days: hyaluronidase 30 U</td>
<td>Complete recovery</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Hirsch et al, 2007<sup><xref ref-type="bibr" rid="bibr22-1090820X13493638">22</xref></sup>
<break/>1 case</td>
<td>Impending necrosis</td>
<td>HA</td>
<td>NLF</td>
<td>6 hours: erythema and discoloration at injection site</td>
<td>6 hours: aspirin 325 mg, nitroglycerin paste, warm compress, and hyaluronidase 30 U</td>
<td>Complete recovery</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Salles et al, 2008<sup><xref ref-type="bibr" rid="bibr13-1090820X13493638">13</xref></sup>
<break/>3 cases</td>
<td>All 3 cases: necrosis</td>
<td>All 3 cases: PMMA</td>
<td>Case 1: nose (tip)
<break/>Case 2: NLF and nose
<break/>Case 3: NLF</td>
<td>Case 1:
<break/>7 days: hyperemia, swelling, and necrosis of ala
<break/>Case 2:
<break/>Immediate: pain
<break/>Later: necrosis of ala and upper lip
<break/>Case 3: necrosis of ala upper and lower lateral lip</td>
<td>All 3 cases: NR</td>
<td>All 3 cases: scarring</td>
<td>Case 1: plastic surgeon
<break/>Case 2:
<break/>dermatologist
<break/>Case 3: plastic surgeon</td>
<td>Brazil</td>
</tr>
<tr>
<td>Inoue et al, 2008<sup><xref ref-type="bibr" rid="bibr16-1090820X13493638">16</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>Collagen</td>
<td>NLF</td>
<td>Immediate: pain at left side of face
<break/>First hours: reddish discoloration
<break/>6 days: necrosis of nasal ala</td>
<td>6 days: IV alprostadil 120 µg/d for 2 wk; surgical debridement</td>
<td>Scarring; reconstruction with skin graft</td>
<td>Plastic surgeon</td>
<td>Japan</td>
</tr>
<tr>
<td>Grunebaum et al, 2009<sup><xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref></sup>
<break/>3 cases</td>
<td>Case 1: necrosis
<break/>Case 2: necrosis
<break/>Case 3: impending necrosis</td>
<td>All 3 cases: HA</td>
<td>Case 1: NLF
<break/>Case 2: NLF
<break/>Case 3: nose (tip)</td>
<td>Case 1:
<break/>1 day: skin irritation; numbness
<break/>3 days: necrosis of nasal ala
<break/>Case 2:
<break/>First hours: pain; dusky erythema
<break/>12 hours: necrosis of nasal ala
<break/>Case 3:
<break/>Immediate: erythema of nose</td>
<td>Case 1:
<break/>3 days: Bacitracin; secondary intention
<break/>Case 2:
<break/>Immediate: hydrocolloid dressing; hyaluronidase 40 U
<break/>Case 3:
<break/>Immediate: nitropaste (for 1 wk) and hyaluronidase (3 times)</td>
<td>Case 1: complete recovery
<break/>Case 2:
<break/>scarring
<break/>Case 3: complete recovery</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Georgescu et al, 2009<sup><xref ref-type="bibr" rid="bibr17-1090820X13493638">17</xref></sup>
<break/>2 cases</td>
<td>Both cases: necrosis</td>
<td>Both cases: CaHa</td>
<td>Case 1: glabella
<break/>Case 2: NLF</td>
<td>Case 1:
<break/>Hours: pain and bruising at injection site
<break/>2 days: necrosis at glabella
<break/>Case 2:
<break/>Same day: pain and swelling over fold; necrosis; ecchymosis</td>
<td>Case 1:
<break/>2 days: PO corticosteroid; nitroglycerin paste (1 wk)
<break/>4 months: microdermabrasion
<break/>Case 2:
<break/>Same day: PO antibiotics and steroids
<break/>Months: Microdermabrasion and hydrocortisone ointment</td>
<td>Both cases: complete recovery</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Winslow, 2009<sup><xref ref-type="bibr" rid="bibr15-1090820X13493638">15</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>CaHa</td>
<td>Nose</td>
<td>Immediate: blanching
<break/>Days: bluish discoloration; ischemic purpura; edema; mild epidermolysis of nose</td>
<td>Nitroglycerin paste (timing not specified)</td>
<td>Complete recovery</td>
<td>Plastic surgeon</td>
<td>United States</td>
</tr>
<tr>
<td>Bachmann et al, 2009<sup><xref ref-type="bibr" rid="bibr28-1090820X13493638">28</xref></sup>
<break/>2 cases</td>
<td>Both cases: necrosis</td>
<td>Both cases: HA</td>
<td>Both cases: glabella</td>
<td>Case 1:
<break/>1 day: erythema; inflammation; abscess formation at injection site
<break/>Case 2:
<break/>Immediate: pain
<break/>1 day: erythema and edema
<break/>5 days: discoloration abscess
<break/>3 weeks: ulceration</td>
<td>NR</td>
<td>Both cases: recovery with
<break/>scarring</td>
<td>NR</td>
<td>Germany</td>
</tr>
<tr>
<td>Humphrey et al, 2009<sup><xref ref-type="bibr" rid="bibr9-1090820X13493638">9</xref></sup>
<break/>2 cases</td>
<td>Both cases: impending necrosis</td>
<td>Both cases: HA</td>
<td>Both cases: nose (tip)</td>
<td>Case 1:
<break/>12 hours: blanching and discoloration at injection site
<break/>Case 2:
<break/>1 week: discoloration and numbness at cold temperature</td>
<td>Case 1:
<break/>12 hours: nitroglycerin paste (1 wk), warm compress, and hyaluronidase (15 U; 3 times)
<break/>Case 2: hyaluronidase (15 U)</td>
<td>Both cases: partial recovery</td>
<td>Otolaryngologist</td>
<td>United States</td>
</tr>
<tr>
<td>Burt et al, 2010<sup><xref ref-type="bibr" rid="bibr18-1090820X13493638">18</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>NLF</td>
<td>1 day: pain and poor perfusion
<break/>3 days: sloughing and ulceration of nasal ala</td>
<td>NR</td>
<td>Complete recovery</td>
<td>Plastic surgeon</td>
<td>United States</td>
</tr>
<tr>
<td>Kassir et al, 2011<sup><xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Cheek</td>
<td>First hours: pain; bluish discoloration
<break/>5 days: slough and eschar of right cheek</td>
<td>5 days: massage; IM, topical, and PO antibiotics; Valtrex; silicone gel</td>
<td>Scarring</td>
<td>Plastic surgeon</td>
<td>United States</td>
</tr>
<tr>
<td>Kim et al, 2011<sup><xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref></sup>
<break/>4 cases</td>
<td>All 4 cases: necrosis</td>
<td>All 4 cases: HA</td>
<td>Case 1: nose (tip)
<break/>Cases 2, 3, and 4: nose (dorsum)</td>
<td>All 4 cases:
<break/>Immediate: pain
<break/>Later: reticular skin discoloration and necrosis of nasal dorsum and tip</td>
<td>Case 1:
<break/>1 day: hyaluronidase
<break/>Case 2:
<break/>1 day: hyaluronidase</td>
<td>All 4 cases: scarring</td>
<td>Plastic surgeon</td>
<td>Korea</td>
</tr>
<tr>
<td>Park et al, 2011<sup><xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref></sup>
<break/>3 cases</td>
<td>All 3 cases: necrosis</td>
<td>All 3 cases: HA</td>
<td>Case 1: nose (sidewall)
<break/>Case 2: NR
<break/>Case 3: NLF</td>
<td>Case 1: NR
<break/>Case 2: necrosis of mentum
<break/>Case 3: necrosis of ala</td>
<td>Case 1:
<break/>3 months: PO antibiotics
<break/>Case 2:
<break/>2 months: surgical excision
<break/>Case 3:
<break/>1 week: oral antibiotics</td>
<td>NR</td>
<td>NR</td>
<td>Korea</td>
</tr>
<tr>
<td>Kim et al, 2011<sup><xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Nose (dorsum and tip)</td>
<td>Hours: swelling and discoloration at injection site
<break/>Days: dark brown and purple discoloration at nasal tip</td>
<td>1 day: filler removal (puncture)
<break/>Days: IV alprostadil and topical antibiotics</td>
<td>Recovery with minimal scarring</td>
<td>Plastic surgeon</td>
<td>Korea</td>
</tr>
<tr>
<td>Dayan et al, 2011<sup><xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref></sup>
<break/>3 cases</td>
<td>Cases 1 and 2: impending necrosis
<break/>Case 3: necrosis</td>
<td>All 3 cases: CaHa</td>
<td>Case 1: NLF, infraorbital region
<break/>Case 2: NLF
<break/>Case 3: NLF</td>
<td>Case 1:
<break/>Immediate: blanching over left cheek, NLF, and left upper lip
<break/>2 days: edema and erythema of left lower face; reticulated vascular congestion of upper lip and left buccal mucosa
<break/>Case 2:
<break/>1 day: tenderness; erythema; drainage at fold
<break/>Case 3:
<break/>1 day: edema; erythema; bruising at fold and malar region
<break/>Later: ulceration at fold</td>
<td>Case 1:
<break/>Immediate: nitroglycerin paste (for 5 days)
<break/>2 days: hyaluronidase 150 U; methylprednisone PO; aspirin 325 mg/d (2 wk); topical oxygen infusion cream
<break/>Case 2:
<break/>1 day: Nitroglycerin paste; antibiotic ointment; hyaluronidase 20 U; aspirin 325 mg/d; PO antibiotics
<break/>4 days: Hyaluronidase 15 U; topical oxygen infusion cream
<break/>Case 3:
<break/>Days: IV and PO antibiotics; PO valacylclovir; topical steroid
<break/>4 weeks: hyaluronidase 40 U; nitroglycerin paste; aspirin 325 mg/d, antacids; topical oxygen infusion cream</td>
<td>Cases 1 and 2: complete recovery
<break/>Case 3: NR</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Park et al, 2011<sup><xref ref-type="bibr" rid="bibr23-1090820X13493638">23</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>NLF</td>
<td>1 hour: erythema on central face
<break/>2 days: Necrosis at nasal tip with pain and tenderness</td>
<td>1 day: hyaluronidase 20 U (once) and warm compress
<break/>2 days: Bacitracin ointment</td>
<td>Complete recovery</td>
<td>Dermatologist</td>
<td>Korea</td>
</tr>
<tr>
<td>Sung et al, 2011<sup><xref ref-type="bibr" rid="bibr14-1090820X13493638">14</xref></sup>
<break/>2 cases</td>
<td>Both cases: necrosis</td>
<td>Both cases: HA</td>
<td>Case 1: nose, forehead, glabella
<break/>Case 2: nose (tip and dorsum)</td>
<td>Case 1:
<break/>1 day: tenderness and erythema
<break/>5 days: necrosis of nasal tip
<break/>Case 2:
<break/>1 day: erythema and pain
<break/>5 days: necrosis of nasal tip and dorsum</td>
<td>Case 1:
<break/>Immediate: IV antibiotics; hydrocolloid dressing
<break/>3 days: adipose-derived stem cells
<break/>Case 2:
<break/>Immediate: hyaluronidase 1000 U; steroid injection
<break/>5 days: IV antibiotics; debridement
<break/>11 days: adipose-derived stem cells</td>
<td>Both cases: recovery with scarring</td>
<td>NR</td>
<td>Korea</td>
</tr>
<tr>
<td>Nettar and Maas, 2012<sup><xref ref-type="bibr" rid="bibr30-1090820X13493638">30</xref></sup>
<break/>1 case</td>
<td>Necrosis</td>
<td>HA</td>
<td>Glabella</td>
<td>Immediate: blanching
<break/>1 day: discoloration; bruising at injection site
<break/>1 week: necrosis of forehead</td>
<td>1 day: arnica cream and ice compress
<break/>1 week: surgical debridement</td>
<td>NR</td>
<td>Plastic surgeon</td>
<td>United States</td>
</tr>
<tr>
<td>de Melo Carpaneda and Carpaneda, 2012<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref></sup>
<break/>5 cases</td>
<td>All 5 cases: necrosis</td>
<td>All 5 cases: PMMA</td>
<td>Case 1: nose (tip)
<break/>Case 2: nose
<break/>Cases 3, 4, and 5: NR</td>
<td>All 5 cases:
<break/>Immediate: intense pain
<break/>1-2 days: white to violet discoloration
<break/>Later: necrosis
<break/>Case 1: necrosis of nasal tip
<break/>Case 2: necrosis of nasal ala and dorsum
<break/>Case 3: necrosis of nasal ala and tip and lips</td>
<td>NR</td>
<td>Cases 1, 3, 4, and 5: NR
<break/>Case 2:
<break/>scarring</td>
<td>NR</td>
<td>Brazil</td>
</tr>
<tr>
<td>Castillo, 1989<sup><xref ref-type="bibr" rid="bibr34-1090820X13493638">34</xref></sup>
<break/>1 case</td>
<td>Blindness</td>
<td>Collagen</td>
<td>Glabella, cheek</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Hanke, 1998<sup><xref ref-type="bibr" rid="bibr43-1090820X13493638">43</xref></sup>
<break/>1 case</td>
<td>Blindness</td>
<td>Collagen</td>
<td>Glabella</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Dermatologist</td>
<td>United States</td>
</tr>
<tr>
<td>Apte et al, 2003<sup><xref ref-type="bibr" rid="bibr36-1090820X13493638">36</xref></sup>
<break/>1 case</td>
<td>Visual impairment</td>
<td>Injectable dermal matrix</td>
<td>Forehead</td>
<td>10 minutes: nausea; diaphoresis; pain in left eye; blurred vision</td>
<td>NR</td>
<td>Vision loss with light perception</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Silva and Curi, 2004<sup><xref ref-type="bibr" rid="bibr40-1090820X13493638">40</xref></sup>
<break/>1 case</td>
<td>Blindness</td>
<td>PMMA</td>
<td>Glabella</td>
<td>Immediate: severe pain and visual loss in right eye</td>
<td>NR</td>
<td>Blindness and total ophthalmoplegia</td>
<td>NR</td>
<td>Brazil</td>
</tr>
<tr>
<td>Kubota and Hirose, 2005<sup><xref ref-type="bibr" rid="bibr38-1090820X13493638">38</xref></sup>
<break/>1 case</td>
<td>Blindness</td>
<td>PMMA</td>
<td>Nose (dorsum)</td>
<td>15 minutes: pain and visual loss in right eye</td>
<td>NR</td>
<td>Blindness</td>
<td>Plastic surgeon</td>
<td>Japan</td>
</tr>
<tr>
<td>Peter and Mennel, 2006<sup><xref ref-type="bibr" rid="bibr35-1090820X13493638">35</xref></sup>
<break/>1 case</td>
<td>Visual impairment</td>
<td>HA</td>
<td>Glabella, cheeks</td>
<td>1 minute: partial loss of vision in inferior right visual field</td>
<td>Immediate: acetazolamide</td>
<td>Complete recovery</td>
<td>NR</td>
<td>United States</td>
</tr>
<tr>
<td>Kang et al, 2007<sup><xref ref-type="bibr" rid="bibr6-1090820X13493638">6</xref></sup>
<break/>1 case</td>
<td>Visual loss and necrosis</td>
<td>NR</td>
<td>Glabella</td>
<td>Immediate visual loss; necrosis of glabellar region</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Korea</td>
</tr>
<tr>
<td>Hwang et al, 2008<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref></sup>
<break/>1 case</td>
<td>Visual loss</td>
<td>NR</td>
<td>Glabella, nose, periorbita</td>
<td>Immediate: visual loss in left eye; erythematous color change at site of injection</td>
<td>Acetazolamide (1 wk) and methylprednisolone (3 d)</td>
<td>Partial recovery with 20/200 visual acuity</td>
<td>NR</td>
<td>Korea</td>
</tr>
<tr>
<td>Kwon et al, 2010<sup><xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup>
<break/>1 case</td>
<td>Blindness, necrosis, stroke lesion</td>
<td>Collagen</td>
<td>Nose (septum)</td>
<td>Immediate: visual loss in left eye; headache
<break/>Later: reticular violet discoloration</td>
<td>Antiplatelet agent and calcium channel blocker</td>
<td>Blindness</td>
<td>NR</td>
<td>Korea</td>
</tr>
<tr>
<td>Sung et al, 2010<sup><xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref></sup>
<break/>1 case</td>
<td>Visual loss, necrosis</td>
<td>CaHa</td>
<td>Nose (dorsum)</td>
<td>Immediate: pain in right eye; ptosis; ophthalmoplegia
<break/>Later: reddish reticular pattern in right eyelid</td>
<td>8 hours: IV antibiotics, topical steroids, and PO corticosteroids</td>
<td>Complete recovery with fixed dilated pupil; minimal scarring</td>
<td>Dermatologist</td>
<td>Korea</td>
</tr>
<tr>
<td>Kim et al, 2011<sup><xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref></sup>
<break/>1 case</td>
<td>Blindness, necrosis</td>
<td>HA</td>
<td>Nose (tip)</td>
<td>Immediate: visual loss in left eye; pain in left upper face; ophthalmoplegia
<break/>2 days: violaceous, ulcerative patches</td>
<td>2 days: IV methylprednisolone; aspirin 100 mg PO</td>
<td>Blindness; recovery from ophthalmoplegia</td>
<td>Plastic surgeon</td>
<td>Korea</td>
</tr>
<tr>
<td>Roberts and Arthurs, 2012<sup><xref ref-type="bibr" rid="bibr39-1090820X13493638">39</xref></sup>
<break/>1 case</td>
<td>Blindness</td>
<td>PLLA</td>
<td>Periorbital region</td>
<td>Immediate: visual loss and pain in left eye
<break/>1 day: nausea; ophthalmoplegia; ptosis</td>
<td>NR</td>
<td>Blindness; recovery from ophthalmoplegia</td>
<td>NR</td>
<td>Canada</td>
</tr>
<tr>
<td>Lemperle et al, 2003<sup><xref ref-type="bibr" rid="bibr7-1090820X13493638">7</xref></sup>
<break/>1 case</td>
<td>Anaphylactic shock</td>
<td>PMMA</td>
<td>NLF</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Italy</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1090820X13493638">
<p>Abbreviations: CaHa, calcium hydroxylapatite; HA, hyaluronic acid; IM, intramuscular; IV, intravenous; NLF, nasolabial fold; NR, not reported; PLLA, poly-L-lactic acid; PMMA, polymethylmethacrylate; PO, per oral.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1090820X13493638" position="float">
<label>Figure 1.</label>
<caption>
<p>Distribution of complications according to injection site and type (necrotic, visual, anaphylactic). Numbers in blue, red, and yellow circles represent the number of cases who had necrotic, visual, and anaphylactic complications, respectively.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig1.tif"/>
</fig>
<fig id="fig2-1090820X13493638" position="float">
<label>Figure 2.</label>
<caption>
<p>Distribution of severe complications according to type of filler. CaHa, calcium hydroxylapatite; HA, hyaluronic acid; PLLA, poly-L-lactic acid; PMMA, polymethylmethacrylate.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig2.tif"/>
</fig>
<sec id="section8-1090820X13493638">
<title>Soft-Tissue Necrosis and Impending Necrosis</title>
<p>There were 39 cases of significant soft-tissue loss and 9 cases of “impending necrosis” (<xref ref-type="table" rid="table1-1090820X13493638">Table 1</xref>). The responsible substances were HA, PMMA, collagen, and CaHa. Common injection sites for these complications were the nose (33.3%; n = 16),<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref>,<xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref>,<xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref><xref ref-type="bibr" rid="bibr9-1090820X13493638"/><xref ref-type="bibr" rid="bibr10-1090820X13493638"/><xref ref-type="bibr" rid="bibr11-1090820X13493638"/><xref ref-type="bibr" rid="bibr12-1090820X13493638"/><xref ref-type="bibr" rid="bibr13-1090820X13493638"/><xref ref-type="bibr" rid="bibr14-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr15-1090820X13493638">15</xref></sup> NLF (31.2%; n = 15),<sup><xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref>,<xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref>,<xref ref-type="bibr" rid="bibr13-1090820X13493638">13</xref>,<xref ref-type="bibr" rid="bibr16-1090820X13493638">16</xref><xref ref-type="bibr" rid="bibr17-1090820X13493638"/><xref ref-type="bibr" rid="bibr18-1090820X13493638"/><xref ref-type="bibr" rid="bibr19-1090820X13493638"/><xref ref-type="bibr" rid="bibr20-1090820X13493638"/><xref ref-type="bibr" rid="bibr21-1090820X13493638"/><xref ref-type="bibr" rid="bibr22-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr23-1090820X13493638">23</xref></sup> and glabella (20.8%; n = 10).<sup><xref ref-type="bibr" rid="bibr17-1090820X13493638">17</xref>,<xref ref-type="bibr" rid="bibr24-1090820X13493638">24</xref><xref ref-type="bibr" rid="bibr25-1090820X13493638"/><xref ref-type="bibr" rid="bibr26-1090820X13493638"/><xref ref-type="bibr" rid="bibr27-1090820X13493638"/><xref ref-type="bibr" rid="bibr28-1090820X13493638"/><xref ref-type="bibr" rid="bibr29-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr30-1090820X13493638">30</xref></sup> Other sites were the cheeks and lips (in 1 and 2 cases, respectively).<sup><xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref><xref ref-type="bibr" rid="bibr32-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr33-1090820X13493638">33</xref></sup> In 4 cases (8.3%), the site of injection was not reported.<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref>,<xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref></sup> Of the 16 nasal injections, 5 were in the nasal tip,<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref>,<xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref><xref ref-type="bibr" rid="bibr9-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref>,<xref ref-type="bibr" rid="bibr13-1090820X13493638">13</xref></sup> 1 was in the lateral nose,<sup><xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref></sup> 3 were in the dorsum,<sup><xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref></sup> and 2 were in the dorsum as well as the tip.<sup><xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref>,<xref ref-type="bibr" rid="bibr14-1090820X13493638">14</xref></sup> One patient had multiple injections to the nose, forehead, and glabella.<sup><xref ref-type="bibr" rid="bibr14-1090820X13493638">14</xref></sup> For the other 4 cases, the specific nasal location was not reported.<sup><xref ref-type="bibr" rid="bibr3-1090820X13493638">3</xref>,<xref ref-type="bibr" rid="bibr9-1090820X13493638">9</xref>,<xref ref-type="bibr" rid="bibr12-1090820X13493638">12</xref>,<xref ref-type="bibr" rid="bibr15-1090820X13493638">15</xref></sup> Details of injection technique and needle size were not described for any case of necrosis.</p>
<p>The symptom most often associated with intravascular injection was immediate pain upon administration of the product. Other acute symptoms included blanching, duskiness, and ecchymosis. In several cases, no signs were noted at the time of injection, and delayed compression of vessels by product was proposed as a possible mechanism of injury.<sup><xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>,<xref ref-type="bibr" rid="bibr21-1090820X13493638">21</xref>,<xref ref-type="bibr" rid="bibr33-1090820X13493638">33</xref></sup></p>
<p>The affected sites showed additional signs of vascular compromise within 1 to 2 days, including erythema, white or violaceous discoloration, edema, bruising, and ongoing pain. In patients with “impending necrosis,” the symptoms and signs improved, sometimes associated with early intervention, and resolved without sequelae.</p>
<p>When soft-tissue loss occurred, slough, ulceration, and eschar developed within 3 to 7 days after injection. The tissue loss occurred directly at the injection site in 46.2% of cases (n = 18) and at the site nourished by the compromised vessel in 28.2% (n = 11). The latter included necrosis developing at the forehead and nose after glabellar injection<sup><xref ref-type="bibr" rid="bibr26-1090820X13493638">26</xref>,<xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref>,<xref ref-type="bibr" rid="bibr30-1090820X13493638">30</xref></sup> and necrosis developing at the nasal ala and lip after NLF injection.<sup><xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref>,<xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref>,<xref ref-type="bibr" rid="bibr13-1090820X13493638">13</xref>,<xref ref-type="bibr" rid="bibr16-1090820X13493638">16</xref>,<xref ref-type="bibr" rid="bibr18-1090820X13493638">18</xref>,<xref ref-type="bibr" rid="bibr23-1090820X13493638">23</xref></sup> In 10 cases (25.6%), the data were insufficient to make a correlation between treatment site and complication site.</p>
<p>A variety of treatments were used, including hyaluronidase, nitroglycerin paste, warm compresses, intravenous (IV) prostaglandins, topical and oral antibiotics, topical and oral corticosteroids, low-molecular-weight heparin, topical oxygen, massage, hydrocolloid dressings, and eventual surgical treatment.<xref ref-type="fn" rid="fn1-1090820X13493638">*</xref> Adipose-derived stem cells were used in 2 cases of nasal tip necrosis.<sup><xref ref-type="bibr" rid="bibr14-1090820X13493638">14</xref></sup> The treatment choice varied according to when the patient was examined by the reporting physician. Because the case reports provided too little detail and the number of cases was small, it was not possible to establish a correlation between treatment initiation and outcome. Of the 39 cases of soft-tissue loss, 11 (28.2%) reportedly healed completely, with no or minimal scarring.<sup><xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref>,<xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref>,<xref ref-type="bibr" rid="bibr15-1090820X13493638">15</xref><xref ref-type="bibr" rid="bibr16-1090820X13493638"/><xref ref-type="bibr" rid="bibr17-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr18-1090820X13493638">18</xref>,<xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>,<xref ref-type="bibr" rid="bibr23-1090820X13493638">23</xref>,<xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref>,<xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref></sup> Fifteen patients (38.5%) had visible scars after complete healing.<sup><xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref>,<xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref>,<xref ref-type="bibr" rid="bibr13-1090820X13493638">13</xref>,<xref ref-type="bibr" rid="bibr25-1090820X13493638">25</xref>,<xref ref-type="bibr" rid="bibr28-1090820X13493638">28</xref>,<xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref></sup> For the remaining 13 cases (33.3%), outcomes were not reported.</p>
</sec>
<sec id="section9-1090820X13493638">
<title>Visual Impairment</title>
<p>There were 12 cases of visual impairment resulting from filler embolism to the ophthalmic vasculature (<xref ref-type="table" rid="table1-1090820X13493638">Table 1</xref>). The injected substances were HA, PMMA, injectable dermal matrix, collagen, PLLA, and CaHa. Specific details regarding injection technique and needle type were not described in any of these reports. The glabella was the most common site yielding visual complications (50%; n = 6), followed by the nose (33.3%; n = 4), forehead (8.3%; n = 1), and periorbital region (8.3%; n = 1). In 3 patients who had injection of the glabella, injections also were made in the nose, cheeks, and periorbital area.<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref>,<xref ref-type="bibr" rid="bibr34-1090820X13493638">34</xref>,<xref ref-type="bibr" rid="bibr35-1090820X13493638">35</xref></sup></p>
<p>In all 12 cases, the signs and symptoms of visual loss developed within minutes of the filler injection. Visual impairment was almost always accompanied by pain in the affected eye.<sup><xref ref-type="bibr" rid="bibr36-1090820X13493638">36</xref><xref ref-type="bibr" rid="bibr37-1090820X13493638"/><xref ref-type="bibr" rid="bibr38-1090820X13493638"/><xref ref-type="bibr" rid="bibr39-1090820X13493638"/><xref ref-type="bibr" rid="bibr40-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref></sup> Other immediate symptoms included diaphoresis, nausea, headache, ophthalmoplegia, and ptosis.<sup><xref ref-type="bibr" rid="bibr36-1090820X13493638">36</xref>,<xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref>,<xref ref-type="bibr" rid="bibr39-1090820X13493638">39</xref>,<xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref>,<xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup> In 4 cases, a violaceous reticular discoloration was evident several days after the injection, which was followed shortly by soft-tissue necrosis in the glabella and nose.<sup><xref ref-type="bibr" rid="bibr6-1090820X13493638">6</xref>,<xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref>,<xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref>,<xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup> One patient experienced ischemic stroke in addition to vision loss.<sup><xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup> Various treatment attempts were used, including diuretic agents, antiplatelet agents, systemic steroids, and aspirin.<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref>,<xref ref-type="bibr" rid="bibr35-1090820X13493638">35</xref>,<xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref>,<xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref>,<xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup> In 7 cases, no information on treatment was provided.<sup><xref ref-type="bibr" rid="bibr6-1090820X13493638">6</xref>,<xref ref-type="bibr" rid="bibr34-1090820X13493638">34</xref>,<xref ref-type="bibr" rid="bibr36-1090820X13493638">36</xref>,<xref ref-type="bibr" rid="bibr38-1090820X13493638">38</xref><xref ref-type="bibr" rid="bibr39-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr40-1090820X13493638">40</xref>,<xref ref-type="bibr" rid="bibr43-1090820X13493638">43</xref></sup> Only 2 of the 12 patients (16.7%) had complete recovery of vision,<sup><xref ref-type="bibr" rid="bibr35-1090820X13493638">35</xref>,<xref ref-type="bibr" rid="bibr41-1090820X13493638">41</xref></sup> and 1 (8.3%) had partial recovery.<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref></sup> Six of the 12 cases (50%) resulted in permanent complete blindness.<sup><xref ref-type="bibr" rid="bibr36-1090820X13493638">36</xref><xref ref-type="bibr" rid="bibr37-1090820X13493638"/><xref ref-type="bibr" rid="bibr38-1090820X13493638"/><xref ref-type="bibr" rid="bibr39-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr40-1090820X13493638">40</xref>,<xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref></sup> In 3 cases (25%), the outcome was not clear.<sup><xref ref-type="bibr" rid="bibr6-1090820X13493638">6</xref>,<xref ref-type="bibr" rid="bibr34-1090820X13493638">34</xref>,<xref ref-type="bibr" rid="bibr43-1090820X13493638">43</xref></sup></p>
</sec>
</sec>
<sec id="section10-1090820X13493638" sec-type="discussion">
<title>Discussion</title>
<p>The increasing demand for soft-tissue augmentation, using a wide variety of fillers, has been documented repeatedly. Since the introduction of collagen as a standard injectable material in the 1980s, a number of filler materials have been manufactured and approved by the FDA. All FDA efficacy testing of newer fillers has been based on the collagen prototype, using split-face studies.<sup><xref ref-type="bibr" rid="bibr44-1090820X13493638">44</xref><xref ref-type="bibr" rid="bibr45-1090820X13493638"/><xref ref-type="bibr" rid="bibr46-1090820X13493638"/><xref ref-type="bibr" rid="bibr47-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr48-1090820X13493638">48</xref></sup> In other words, new fillers merely had to meet or exceed the safety and efficacy standards of collagen products when collagen was injected into 1 NLF and the filler tested in the contralateral fold. Direct comparisons were then made between the duration of soft-tissue correction and the complications that occurred. Since 2010, collagen filler products have not been available in the United States, with the exception of bovine collagen, used as a carrier for PMMA microspheres.</p>
<p>The FDA has approved a variety of different filler materials, each with a distinct composition, injection profile, and duration of effect. Many of them are in use off-label at the discretion of the physician. Currently, HA is the most commonly used injectable, followed by CaHa and PLLA.<sup><xref ref-type="bibr" rid="bibr1-1090820X13493638">1</xref></sup> Therefore, it is not surprising that HA products are implicated most frequently in severe complications. These fillers also have different mechanisms of action and different periods of persistence in tissue. Among the temporary materials, HA remains in the tissue for 4 to 12 months, whereas collagen typically lasts only 2 to 4 months. Recent studies have shown that reinjection 4 to 5 months following initial treatment significantly increases the efficacy of HA products.<sup><xref ref-type="bibr" rid="bibr49-1090820X13493638">49</xref><xref ref-type="bibr" rid="bibr50-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr51-1090820X13493638">51</xref></sup> CaHa and PLLA are considered semipermanent fillers and may last 1 to 2 years in tissue. The only FDA-approved permanent filler is PMMA. Although the collagen carrier of this filler resorbs over time, the microspheres do not degrade, resorb, or dissolve, yielding permanent correction of wrinkles.</p>
<p>Even though soft-tissue fillers are generally safe, undesirable effects can occur with any type of filler. Adverse effects may result from injection techniques (eg, overcorrection, irregularities, Tyndall effect, intravascular injection) or can be host-initiated local events. Some of these effects may resolve with time, but others will require intervention based on severity and/or the type of filler used. Visual impairment, soft-tissue necrosis, permanent scarring, and anaphylaxis are rare but severe events.</p>
<sec id="section11-1090820X13493638">
<title>Determining the Incidence of Complications</title>
<p>The lack of an organized database, combined with the fact that the injections generally are not performed in hospitals or outpatient facilities, makes it very difficult to obtain accurate data on complications, although several attempts have been made to estimate the number. Hanke et al<sup><xref ref-type="bibr" rid="bibr29-1090820X13493638">29</xref></sup> published data pertaining to a 7-year period (1982-1989) and reported an average annual incidence of 0.09% for necrosis and abscess after collagen treatments. In 2002, based on a review of manufacturer-supplied data, Friedman et al<sup><xref ref-type="bibr" rid="bibr24-1090820X13493638">24</xref></sup> examined the safety profile of HA injections performed outside the United States. The overall incidence of AE was reportedly 0.15% in 1999 and 0.06% in 2000. Narins et al<sup><xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref></sup> used information from spontaneous drug AE reporting (SAER) systems to identify the more severe HA-related complications and reviewed the published cases in the United States in 2004. They estimated the incidence to be less than 0.001%.<sup><xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref></sup> Current statistics on fillers and associated complications can be gathered readily from company-based data as well as national societies. Considering the widespread use of fillers by many specialties, the large variety of brands worldwide, and unreliable methods of data collection, determining an accurate incidence of complications is a challenging task. When combining procedural data from ASAPS and ASDS statistics from 2010 to 2011, the number of filler treatments performed by plastic surgeons and dermatologists totaled approximately 4 658 982 for the 2-year period.<sup><xref ref-type="bibr" rid="bibr1-1090820X13493638">1</xref>,<xref ref-type="bibr" rid="bibr2-1090820X13493638">2</xref></sup> In the same timeframe, the number of cases of severe complications in the United States reported by the same specialties was only 5,<sup><xref ref-type="bibr" rid="bibr18-1090820X13493638">18</xref>,<xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>,<xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref></sup> yielding an estimated incidence of 0.0001%. Until a database is established by our professional societies, which allows for prospective data entry, the true incidence of complications will remain unknown.</p>
</sec>
<sec id="section12-1090820X13493638">
<title>Treatment of Mild, Moderate, and Self-Limited Complications</title>
<p>A review of the Manufacturer and User Facility Device Experience (MAUDE) database from 2003 to 2008 demonstrated that the most common AE associated with fillers were swelling, erythema, and inflammatory reactions such as granulomas and nodules.<sup><xref ref-type="bibr" rid="bibr52-1090820X13493638">52</xref></sup> Other mild to moderate complications included hypersensitivity, infection, bruising, Tyndall effect, pain, blisters, beading of filler under skin, numbness, and migration.</p>
<p>Swelling and ecchymosis may develop at the time of injection and usually resolve spontaneously.<sup><xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref>,<xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref><xref ref-type="bibr" rid="bibr54-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr55-1090820X13493638">55</xref></sup> Erythema also is commonly transient but, on occasion, permanent telangiectasias may occur at the injection site. If this happens, treatment with intense pulsed light therapy or pulsed dye laser can be initiated.<sup><xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref>,<xref ref-type="bibr" rid="bibr57-1090820X13493638">57</xref></sup> Nodules and erythema that persist beyond the first few days of treatment may be signs of inflammation.<sup><xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref>,<xref ref-type="bibr" rid="bibr57-1090820X13493638">57</xref>,<xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref></sup> In these cases, massage and administration of hyaluronidase for HA products have proven helpful.<sup><xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref></sup> After infection is ruled out, intralesional or topical corticosteroids also may be used.<sup><xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref>,<xref ref-type="bibr" rid="bibr57-1090820X13493638">57</xref></sup></p>
<p>Lumps or beading usually appear shortly after treatment in the form of well-confined palpable lesions, which can result from injection in areas of thin soft-tissue coverage (eg, eyelids, nasojugal region, lips), injection of too much material, clumping of filler, or dislocation by movement of muscles.<sup><xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref>,<xref ref-type="bibr" rid="bibr57-1090820X13493638">57</xref>,<xref ref-type="bibr" rid="bibr59-1090820X13493638">59</xref>,<xref ref-type="bibr" rid="bibr60-1090820X13493638">60</xref></sup> Common sites for irregularities and lumps include the lips and the perioral area. The lips are an area of high mobility and thin mucosa. Once irregularities in the mucosa of the lips occur, they are difficult to correct if semipermanent fillers have been injected. Therefore, the use of semipermanent fillers in this area is discouraged<sup><xref ref-type="bibr" rid="bibr61-1090820X13493638">61</xref>,<xref ref-type="bibr" rid="bibr62-1090820X13493638">62</xref></sup> (<xref ref-type="fig" rid="fig3-1090820X13493638">Figure 3</xref>). The tear trough and periorbital regions also are considered high risk and are prone to display irregularities if injected superficially.<sup><xref ref-type="bibr" rid="bibr54-1090820X13493638">54</xref>,<xref ref-type="bibr" rid="bibr63-1090820X13493638">63</xref>,<xref ref-type="bibr" rid="bibr64-1090820X13493638">64</xref></sup> Measures to avoid visibility of the implanted material include firm massage and meticulous placement of filler in the deep supraperiosteal plane.<sup><xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref>,<xref ref-type="bibr" rid="bibr65-1090820X13493638">65</xref></sup> Relatively short-term fillers such as HA products are preferable for these high-risk regions. An additional benefit of using HA in these areas is that irregularities can be reversed with hyaluronidase (15-300 U). Semipermanent fillers such as CaHa and PLLA have the advantage of being longer lasting than HA; however, with this benefit comes a disadvantage. If overcorrection occurs, irregularity and nodule formation can develop; these problems are more persistent and difficult to treat. To prevent technique-related complications, injection should be in the subdermal plane, bolus injection should be avoided, and injection sites should be massaged after injection.<sup><xref ref-type="bibr" rid="bibr66-1090820X13493638">66</xref>,<xref ref-type="bibr" rid="bibr67-1090820X13493638">67</xref></sup> Treatments for semipermanent fillers include direct excision of the filler, needle disruption and unroofing of lumps, and waiting for the product to absorb.<sup><xref ref-type="bibr" rid="bibr66-1090820X13493638">66</xref><xref ref-type="bibr" rid="bibr67-1090820X13493638"/><xref ref-type="bibr" rid="bibr68-1090820X13493638"/><xref ref-type="bibr" rid="bibr69-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr70-1090820X13493638">70</xref></sup> Lumps caused by PLLA or PMMA respond well to intralesional steroid injections, but steroids are less effective for CaHa.<sup><xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref></sup></p>
<fig id="fig3-1090820X13493638" position="float">
<label>Figure 3.</label>
<caption>
<p>This 47-year-old woman, who had been injected with calcium hydroxylapatite at another clinic, presented 4 months later with white nodules along the lower lip. The granules were palpable and visible (arrows) just under the mucosa of the lower lip. The patient refused surgical excision.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig3.tif"/>
</fig>
<p>True granulomas appear late, after weeks or months, and respond well to intralesional steroids<sup><xref ref-type="bibr" rid="bibr55-1090820X13493638">55</xref><xref ref-type="bibr" rid="bibr56-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr57-1090820X13493638">57</xref>,<xref ref-type="bibr" rid="bibr60-1090820X13493638">60</xref>,<xref ref-type="bibr" rid="bibr65-1090820X13493638">65</xref></sup> or incision and drainage. The reported rate of granuloma is 0.01% to 1%.<sup><xref ref-type="bibr" rid="bibr48-1090820X13493638">48</xref>,<xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref></sup> Recently, there has been discussion on the role of biofilms in causing delayed nodule formation.<sup><xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref>,<xref ref-type="bibr" rid="bibr55-1090820X13493638">55</xref>,<xref ref-type="bibr" rid="bibr71-1090820X13493638">71</xref><xref ref-type="bibr" rid="bibr72-1090820X13493638"/><xref ref-type="bibr" rid="bibr73-1090820X13493638"/><xref ref-type="bibr" rid="bibr74-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr75-1090820X13493638">75</xref></sup> Biofilms are accumulations of microorganisms within a self-developed matrix, which are irreversibly adherent to one another and to a variety of surfaces.<sup><xref ref-type="bibr" rid="bibr75-1090820X13493638">75</xref>,<xref ref-type="bibr" rid="bibr76-1090820X13493638">76</xref></sup> All fillers, especially longer-lasting products, are potential surfaces for biofilm formation. Because their growth rate is slow, biofilms usually are not identifiable by culture. They may present as sterile abscesses or cause a chronic inflammatory response.<sup><xref ref-type="bibr" rid="bibr55-1090820X13493638">55</xref>,<xref ref-type="bibr" rid="bibr75-1090820X13493638">75</xref>,<xref ref-type="bibr" rid="bibr77-1090820X13493638">77</xref><xref ref-type="bibr" rid="bibr78-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr79-1090820X13493638">79</xref></sup> Infections resulting from biofilms are notoriously difficult to treat because of their slow bacterial metabolism and their secretion of a protective matrix.<sup><xref ref-type="bibr" rid="bibr77-1090820X13493638">77</xref></sup> Hyaluronidase has been shown to help break down the matrix, thereby decreasing the biofilm mass.<sup><xref ref-type="bibr" rid="bibr80-1090820X13493638">80</xref></sup> Dayan et al<sup><xref ref-type="bibr" rid="bibr75-1090820X13493638">75</xref></sup> reported successful treatment of resistant inflammatory reactions with hyaluronidase regardless of the filler used. Other treatment options for biofilms are prolonged use of antibiotics, administration of intralesional 5-fluorouracil, and intralesional laser therapy with a 532-nm or 808-nm laser.<sup><xref ref-type="bibr" rid="bibr77-1090820X13493638">77</xref>,<xref ref-type="bibr" rid="bibr81-1090820X13493638">81</xref><xref ref-type="bibr" rid="bibr82-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr83-1090820X13493638">83</xref></sup> With respect to antimicrobials, 2-drug therapy with a quinolone and third-generation macrolide has been recommended.<sup><xref ref-type="bibr" rid="bibr55-1090820X13493638">55</xref>,<xref ref-type="bibr" rid="bibr77-1090820X13493638">77</xref></sup> To prevent biofilm formation or other soft-tissue infections, care should be taken to avoid any contamination during implantation. A sterile technique should be used when reconstituting or diluting the product, the injection site should be prepared with topical antiseptics, injection to infected areas should be avoided, and makeup and other potential contaminants on the skin should be removed before injection.<sup><xref ref-type="bibr" rid="bibr67-1090820X13493638">67</xref>,<xref ref-type="bibr" rid="bibr74-1090820X13493638">74</xref>,<xref ref-type="bibr" rid="bibr84-1090820X13493638">84</xref></sup> Moreover, the following should be avoided: injection of high-volume bolus material, breaching of mucosa, and injection through previous filler.<sup><xref ref-type="bibr" rid="bibr75-1090820X13493638">75</xref>,<xref ref-type="bibr" rid="bibr76-1090820X13493638">76</xref></sup> However, it is important to note that cases of recurrent, unexplained infections can be the result of other pathology. Factitious ulceration also should be considered in this setting (<xref ref-type="fig" rid="fig4-1090820X13493638">Figure 4</xref>).</p>
<fig id="fig4-1090820X13493638" position="float">
<label>Figure 4.</label>
<caption>
<p>(A) Two weeks after injection of collagen to the nasolabial folds, this 42-year-old woman complained of nodules and ulceration, which persisted for another 2 weeks. She had multiple erythematous and partially ulcerated lesions (arrows) on other areas of the face, which suggested factitious disorder. She was treated with oral antibiotics and steroids. (B) Ten months after excision of the ulcerated lesion and granuloma on the right nasolabial fold (left arrow). The rest of the lesions healed by secondary intention (right arrow). (C) Pathologic findings of the excised area were consistent with prurigo nodularis (Picker nodule).</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig4.tif"/>
</fig>
<p>Hypersensitivity to fillers may trigger angioedema or anaphylactic reactions.<sup><xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref>,<xref ref-type="bibr" rid="bibr63-1090820X13493638">63</xref>,<xref ref-type="bibr" rid="bibr74-1090820X13493638">74</xref>,<xref ref-type="bibr" rid="bibr85-1090820X13493638">85</xref></sup> Delayed hypersensitivity reactions are usually self-limited systemic events that resolve without any sequelae but, depending on the presentation, oral steroid treatment may be required. Although collagen itself is no longer available, other collagen-containing products (such as PMMA in collagen suspension) require skin testing prior to administration.</p>
<p>Mild to moderate complications are usually self-limited. Consensus treatments for complications that fail to resolve within several weeks include hyaluronidase injection, intralesional steroids, and light-based therapies. Systemic steroids, systemic antibiotics, and/or surgical excision may be required depending on the extent of the problem. An algorithm for the treatment of mild to moderate complications is presented in <xref ref-type="fig" rid="fig5-1090820X13493638">Figure 5</xref>.</p>
<fig id="fig5-1090820X13493638" position="float">
<label>Figure 5.</label>
<caption>
<p>Algorithm for treatment of mild to moderate complications following filler injections. 5-FU, 5-fluorouracil; HA, hyaluronic acid; IPL, intense pulsed light; I&amp;D, incision and drainage.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig5.tif"/>
</fig>
</sec>
<sec id="section13-1090820X13493638">
<title>Treatment and Prevention of Severe Complications</title>
<p>Vascular-related events are the complications most likely to result in permanent sequelae. They can occur from intravascular embolism of injected material, direct needle injury to vessels, or external compression of vessels by surrounding filler<sup><xref ref-type="fn" rid="fn2-1090820X13493638">†</xref></sup> (<xref ref-type="fig" rid="fig6-1090820X13493638">Figure 6</xref>). Inadvertent injections of the angular, dorsal nasal, or supratrochlear artery are most likely to lead to an ischemic response that results in necrosis.<sup><xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref>,<xref ref-type="bibr" rid="bibr54-1090820X13493638">54</xref>,<xref ref-type="bibr" rid="bibr65-1090820X13493638">65</xref></sup></p>
<fig id="fig6-1090820X13493638" position="float">
<label>Figure 6.</label>
<caption>
<p>(A) This 62-year-old man had inadvertent intravascular injection of poly-L-lactic acid during treatment of the cheeks. Warm compresses were applied immediately. (B) Three months after injection. The patient recovered without any sequelae.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig6.tif"/>
</fig>
<p>Appropriate treatment should be started immediately upon suspicion of vascular compromise. Injection should be stopped, and the area should be massaged and warm compresses applied to increase vasodilatation.<sup><xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref>,<xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref></sup> Utilization of nitroglycerine paste and hyaluronidase also is advocated for early presenting cases. Other treatments include systemic or topical steroids to reduce associated inflammation, thereby mitigating the degree of injury.<sup><xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>,<xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref>,<xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref>,<xref ref-type="bibr" rid="bibr65-1090820X13493638">65</xref></sup> Although aspirin and IV prostaglandins have been suggested, their efficacy has not been proven.<sup><xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref>,<xref ref-type="bibr" rid="bibr16-1090820X13493638">16</xref>,<xref ref-type="bibr" rid="bibr21-1090820X13493638">21</xref>,<xref ref-type="bibr" rid="bibr22-1090820X13493638">22</xref></sup> Other options with unproven efficacy are filler removal via puncture and low-molecular-weight heparin.<sup><xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref>,<xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>,<xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref></sup> Of course, patients with any vascular complication should remain under extremely close care. The treatment measures are aimed at dissolving the product, facilitating blood flow, and promoting vasodilation. Dayan et al<sup><xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref></sup> have suggested the use of hyaluronidase in all cases of vascular compromise, independent of the filler type, due to its edema-reducing benefits and theoretical advantage in reducing occluding vessel pressure.</p>
<p>Although we were not able to correlate the time of therapy initiation with outcomes due to the insufficient data of case reports, it is well known that prompt intervention is crucial. In an experimental study, Kim et al<sup><xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref></sup> found that the use of hyaluronidase within 4 hours of injection proved to be a successful salvage procedure for HA fillers. Once necrosis has occurred, debridement and wound care are required to minimize scarring. Typically, an eschar develops, which heals over several weeks by granulation and reepithelialization. The means of surgical reconstruction are site specific.</p>
<p>Vascular complications are best avoided with appropriate training and injection techniques. The most important controllable factor for practitioners is the speed of injection. Filler should be injected slowly and the needle withdrawn using the least amount of pressure.<sup><xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref></sup> Other precautions include aspiration before injection, delivery of material at different points, and injection of small volumes per pass.<sup><xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref>,<xref ref-type="bibr" rid="bibr67-1090820X13493638">67</xref>,<xref ref-type="bibr" rid="bibr74-1090820X13493638">74</xref>,<xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref>,<xref ref-type="bibr" rid="bibr87-1090820X13493638">87</xref></sup> The use of small-caliber needles has been advocated by some since they slow the speed of injection.<sup><xref ref-type="bibr" rid="bibr58-1090820X13493638">58</xref>,<xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref></sup> The use of blunt needles in high-risk regions such as the glabella, nose, and NLF is another means of reducing injury to vessels<sup><xref ref-type="bibr" rid="bibr88-1090820X13493638">88</xref><xref ref-type="bibr" rid="bibr89-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr90-1090820X13493638">90</xref></sup> (<xref ref-type="fig" rid="fig7-1090820X13493638">Figure 7</xref>). The injection technique differs with blunt tips: there is less movement and less subcision and consequently less trauma.<sup><xref ref-type="bibr" rid="bibr90-1090820X13493638">90</xref></sup> However, these cannulae are prone to bend with multiple passes, and some planes may be difficult to breach with the blunt tip, resulting in excess accumulation of the product. Use of an epinephrine-containing product has inherent risks and benefits. Although it may mask a complication because of its blanching effect, it also may decrease the chance of bruising by constricting the blood vessels.<sup><xref ref-type="bibr" rid="bibr26-1090820X13493638">26</xref>,<xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref></sup></p>
<fig id="fig7-1090820X13493638" position="float">
<label>Figure 7.</label>
<caption>
<p>The use of a blunt-tip cannula during filler injection reduces the risk of intravascular penetration.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig7.tif"/>
</fig>
<p>Consensus treatment of suspected intravascular injection includes immediate cessation of the injection, massage, warm compresses, topical nitroglycerine paste, and hyaluronidase (regardless of filler type). Other suggestions (but without proven efficacy) include removal of filler via puncture, systemic or topical steroids, aspirin, low-molecular-weight heparin, and IV prostaglandins. An algorithm for the treatment of suspected intravascular injection is presented in <xref ref-type="fig" rid="fig8-1090820X13493638">Figure 8</xref>.</p>
<fig id="fig8-1090820X13493638" position="float">
<label>Figure 8.</label>
<caption>
<p>Algorithm for treatment of severe complications following filler injections. *Hyaluronidase is recommended independent of filler type. IL, intralesional; IV, intravenous; LMWH, low-molecular-weight heparin; PO, per oral.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13493638-fig8.tif"/>
</fig>
<p>The underlying mechanism for visual impairment after facial injection is related to retrograde embolization from peripheral vessels into the ophthalmic arterial system.<sup><xref ref-type="bibr" rid="bibr5-1090820X13493638">5</xref>,<xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref><xref ref-type="bibr" rid="bibr38-1090820X13493638"/><xref ref-type="bibr" rid="bibr39-1090820X13493638"/><xref ref-type="bibr" rid="bibr40-1090820X13493638"/><xref ref-type="bibr" rid="bibr41-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref>,<xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref>,<xref ref-type="bibr" rid="bibr91-1090820X13493638">91</xref></sup> Intra-arterially injected material is displaced via a high injection pressure past the origin of the retinal artery, and when the plunger is released, it is propelled into this system. Even a very small amount of material can cause embolization of the retinal artery because it is an end artery with no physiologic anastomoses.<sup><xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref>,<xref ref-type="bibr" rid="bibr92-1090820X13493638">92</xref></sup> The retina is also very sensitive to ischemia.<sup><xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref>,<xref ref-type="bibr" rid="bibr92-1090820X13493638">92</xref></sup> Factors contributing to this phenomenon are high injection pressures, the distance between injection site and retinal circulation, and the amount of injected material.<sup><xref ref-type="bibr" rid="bibr37-1090820X13493638">37</xref>,<xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref></sup></p>
<p>If symptoms of visual impairment occur, the goal is to reduce intraocular pressure and dislodge the embolus to improve perfusion of the retina and optic nerve. There is no single reliable treatment for iatrogenic retinal artery embolism.<sup><xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref></sup> Recommended measures include immediate ophthalmologic consultation, ocular massage, timolol eye drops, diuretics, hemodilution (with hydroxyethyl starch), corticosteroids, calcium channel blockers, anticoagulation, and needle decompression of the anterior chamber.<sup><xref ref-type="bibr" rid="bibr42-1090820X13493638">42</xref>,<xref ref-type="bibr" rid="bibr86-1090820X13493638">86</xref>,<xref ref-type="bibr" rid="bibr93-1090820X13493638">93</xref></sup> Other modalities that have been used after fat embolism to the retinal artery include carbon dioxide and oxygen therapy,<sup><xref ref-type="bibr" rid="bibr94-1090820X13493638">94</xref></sup> thrombolysis with urokinase,<sup><xref ref-type="bibr" rid="bibr95-1090820X13493638">95</xref></sup> and vasodilation.<sup><xref ref-type="bibr" rid="bibr96-1090820X13493638">96</xref></sup> However, attempts to reverse retinal artery occlusion are often unsuccessful. It is unclear whether the recovery is due to timely initiation of therapy, transient embolism, or favorable location of infarct in the retina. Unfortunately, in cases of vision loss, the outcome is grave regardless of the treatment rendered.</p>
</sec>
</sec>
<sec id="section14-1090820X13493638" sec-type="conclusions">
<title>Conclusions</title>
<p>The soft-tissue fillers approved for use in the United States have an excellent safety profile, which is reflected by their increasing use. Although serious complications are rare, they can occur. Whenever fillers are placed, the products needed to treat complications should be readily available. These should include, but not be limited to, hyaluronidase, nitroglycerine paste, and warm compresses. Physicians also should be aware of the high-risk regions of the midface, as identified in the present review. Injections to the nose, NLF, and glabella require additional caution. Familiarity with the prevention, presentation, and immediate treatment of these rare events is essential for attaining the best possible outcome.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Disclosures</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and publication of this article.</p>
</fn>
<fn fn-type="other" id="fn1-1090820X13493638">
<label>*</label>
<p>References <xref ref-type="bibr" rid="bibr4-1090820X13493638">4</xref>, <xref ref-type="bibr" rid="bibr8-1090820X13493638">8</xref>, <xref ref-type="bibr" rid="bibr9-1090820X13493638">9</xref>, <xref ref-type="bibr" rid="bibr11-1090820X13493638">11</xref>, <xref ref-type="bibr" rid="bibr12-1090820X13493638">12</xref>, <xref ref-type="bibr" rid="bibr15-1090820X13493638">15</xref><xref ref-type="bibr" rid="bibr16-1090820X13493638"/>-<xref ref-type="bibr" rid="bibr17-1090820X13493638">17</xref>, <xref ref-type="bibr" rid="bibr20-1090820X13493638">20</xref>, <xref ref-type="bibr" rid="bibr23-1090820X13493638">23</xref>, <xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref>, <xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref>, <xref ref-type="bibr" rid="bibr32-1090820X13493638">32</xref>.</p>
</fn>
<fn fn-type="other" id="fn2-1090820X13493638">
<label>†</label>
<p>References <xref ref-type="bibr" rid="bibr10-1090820X13493638">10</xref>, <xref ref-type="bibr" rid="bibr16-1090820X13493638">16</xref>, <xref ref-type="bibr" rid="bibr18-1090820X13493638">18</xref>, <xref ref-type="bibr" rid="bibr26-1090820X13493638">26</xref>, <xref ref-type="bibr" rid="bibr27-1090820X13493638">27</xref>, <xref ref-type="bibr" rid="bibr31-1090820X13493638">31</xref>, <xref ref-type="bibr" rid="bibr53-1090820X13493638">53</xref>, <xref ref-type="bibr" rid="bibr56-1090820X13493638">56</xref>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1090820X13493638">
<label>1.</label>
<citation citation-type="web">
<collab>American Society for Aesthetic Plastic Surgery</collab>. <article-title>ASAPS National Cosmetic Surgery Databank Statistics</article-title> <year>2012</year>. <ext-link ext-link-type="uri" xlink:href="http://www.surgery.org/sites/default/files/ASAPS-2012-Stats.pdf">http://www.surgery.org/sites/default/files/ASAPS-2012-Stats.pdf</ext-link>. <access-date>Accessed May 6, 2013</access-date>.</citation>
</ref>
<ref id="bibr2-1090820X13493638">
<label>2.</label>
<citation citation-type="web">
<collab>American Society for Dermatologic Surgery</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.asds.net">http://www.asds.net</ext-link>. <access-date>Accessed October 10, 2012</access-date>.</citation>
</ref>
<ref id="bibr3-1090820X13493638">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Melo Carpaneda</surname><given-names>E</given-names></name>
<name><surname>Carpaneda</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Adverse results with PMMA fillers</article-title>. <source>Aesthetic Plast Surg</source>. <year>2012</year>;<volume>36</volume>:<fpage>955</fpage>-<lpage>963</lpage>.</citation>
</ref>
<ref id="bibr4-1090820X13493638">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>TH</given-names></name>
<name><surname>Seo</surname><given-names>SW</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name><etal/>
</person-group>. <article-title>Clinical experience with hyaluronic acid–filler complications</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2011</year>;<volume>64</volume>:<fpage>892</fpage>-<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr5-1090820X13493638">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>YH</given-names></name>
<name><surname>Hwang</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Branch retinal artery occlusion after periocular dermal filler injection</article-title>. <source>Retin Cases Brief Rep</source>. <year>2008</year>;<volume>2</volume>:<fpage>338</fpage>-<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr6-1090820X13493638">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>YS</given-names></name>
<name><surname>Kim</surname><given-names>JW</given-names></name>
<name><surname>Choi</surname><given-names>WS</given-names></name><etal/>
</person-group>. <article-title>A case of sudden unilateral vision loss following injection of filler into the glabella</article-title>. <source>Korean J Dermatol</source>. <year>2007</year>;<volume>45</volume>:<fpage>381</fpage>-<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr7-1090820X13493638">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Romano</surname><given-names>JJ</given-names></name>
<name><surname>Busso</surname><given-names>M</given-names></name>
</person-group>. <article-title>Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications</article-title>. <source>Dermatol Surg</source>. <year>2003</year>;<volume>29</volume>:<fpage>573</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr8-1090820X13493638">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grunebaum</surname><given-names>LD</given-names></name>
<name><surname>Bogdan Allemann</surname><given-names>I</given-names></name>
<name><surname>Dayan</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>The risk of alar necrosis associated with dermal filler injection</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1635</fpage>-<lpage>1640</lpage>.</citation>
</ref>
<ref id="bibr9-1090820X13493638">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humphrey</surname><given-names>CD</given-names></name>
<name><surname>Arkins</surname><given-names>JP</given-names></name>
<name><surname>Dayan</surname><given-names>SH</given-names></name>
</person-group>. <article-title>Soft tissue fillers in the nose</article-title>. <source>Aesthetic Surg J</source>. <year>2009</year>;<volume>29</volume>:<fpage>477</fpage>-<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr10-1090820X13493638">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>DW</given-names></name>
<name><surname>Yoon</surname><given-names>ES</given-names></name>
<name><surname>Ji</surname><given-names>YH</given-names></name><etal/>
</person-group>. <article-title>Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2011</year>;<volume>64</volume>:<fpage>1590</fpage>-<lpage>1595</lpage>.</citation>
</ref>
<ref id="bibr11-1090820X13493638">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SG</given-names></name>
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Lee</surname><given-names>SI</given-names></name><etal/>
</person-group>. <article-title>Salvage of nasal skin in a case of venous compromise after hyaluronic acid filler injection using prostaglandin E</article-title>. <source>Dermatol Surg</source>. <year>2011</year>;<volume>37</volume>:<fpage>1817</fpage>-<lpage>1819</lpage>.</citation>
</ref>
<ref id="bibr12-1090820X13493638">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Monheit</surname><given-names>G</given-names></name>
</person-group>. <article-title>Fibrel: soft tissue augmentation</article-title>. In: <person-group person-group-type="editor">
<name><surname>Klein</surname><given-names>AW</given-names></name>
</person-group>, ed. <source>Soft Tissue Augmentation in clinical practice: procedures and techniques</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Marcel Dekker</publisher-name>; <volume>1998</volume>:<fpage>155</fpage>-<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr13-1090820X13493638">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salles</surname><given-names>AG</given-names></name>
<name><surname>Lotierzo</surname><given-names>PH</given-names></name>
<name><surname>Gemperli</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Complications after polymethylmethacrylate injections: report of 32 cases</article-title>. <source>Plast Reconstr Surg</source>. <year>2008</year>;<volume>121</volume>:<fpage>1811</fpage>-<lpage>1820</lpage>.</citation>
</ref>
<ref id="bibr14-1090820X13493638">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sung</surname><given-names>HM</given-names></name>
<name><surname>Suh</surname><given-names>IS</given-names></name>
<name><surname>Lee</surname><given-names>HB</given-names></name><etal/>
</person-group>. <article-title>Case reports of adipose-derived stem cell therapy for nasal skin necrosis after filler injection</article-title>. <source>Arch Plast Surg</source>. <year>2011</year>;<volume>39</volume>:<fpage>51</fpage>-<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr15-1090820X13493638">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winslow</surname><given-names>CP</given-names></name>
</person-group>. <article-title>The management of dermal filler complications</article-title>. <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>124</fpage>-<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr16-1090820X13493638">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>K</given-names></name>
<name><surname>Sato</surname><given-names>K</given-names></name>
<name><surname>Matsumoto</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Arterial embolization and skin necrosis of the nasal ala following injection of dermal fillers</article-title>. <source>Plast Reconstr Surg</source>. <year>2008</year>;<volume>121</volume>:<fpage>127e</fpage>-<lpage>128e</lpage>.</citation>
</ref>
<ref id="bibr17-1090820X13493638">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Georgescu</surname><given-names>D</given-names></name>
<name><surname>Jones</surname><given-names>Y</given-names></name>
<name><surname>McCann</surname><given-names>JD</given-names></name><etal/>
</person-group>. <article-title>Skin necrosis after calcium hydroxylapatite injection into the glabellar and nasolabial folds</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>498</fpage>-<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr18-1090820X13493638">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burt</surname><given-names>B</given-names></name>
<name><surname>Nakra</surname><given-names>T</given-names></name>
<name><surname>Isaacs</surname><given-names>DK</given-names></name><etal/>
</person-group>. <article-title>Alar necrosis after facial injection of hyaluronic acid</article-title>. <source>Plast Reconstr Surg</source>. <year>2010</year>;<volume>125</volume>:<fpage>199e</fpage>-<lpage>200e</lpage>.</citation>
</ref>
<ref id="bibr19-1090820X13493638">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellman</surname><given-names>B</given-names></name>
</person-group>. <article-title>Complication following suspected intra-arterial injection of Restylane</article-title>. <source>Aesthetic Surg J</source>. <year>2006</year>;<volume>26</volume>:<fpage>304</fpage>-<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr20-1090820X13493638">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dayan</surname><given-names>SH</given-names></name>
<name><surname>Arkins</surname><given-names>JP</given-names></name>
<name><surname>Mathison</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Management of impending necrosis associated with soft tissue filler injections</article-title>. <source>J Drugs Dermatol</source>. <year>2011</year>;<volume>10</volume>:<fpage>1007</fpage>-<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr21-1090820X13493638">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Lupo</surname><given-names>M</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name><etal/>
</person-group>. <article-title>Delayed presentation of impending necrosis following soft tissue augmentation with hyaluronic acid and successful management with hyaluronidase</article-title>. <source>J Drugs Dermatol</source>. <year>2007</year>;<volume>6</volume>:<fpage>325</fpage>-<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr22-1090820X13493638">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
<name><surname>Carruthers</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>:<fpage>357</fpage>-<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr23-1090820X13493638">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>KY</given-names></name>
<name><surname>Son</surname><given-names>IP</given-names></name>
<name><surname>Li</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Reticulated erythema after nasolabial fold injection with hyaluronic acid: the importance of immediate attention</article-title>. <source>Dermatol Surg</source>. <year>2011</year>;<volume>37</volume>:<fpage>1697</fpage>-<lpage>1699</lpage>.</citation>
</ref>
<ref id="bibr24-1090820X13493638">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>PM</given-names></name>
<name><surname>Mafong</surname><given-names>EA</given-names></name>
<name><surname>Kauvar</surname><given-names>AN</given-names></name><etal/>
</person-group>. <article-title>Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation</article-title>. <source>Dermatol Surg</source>. <year>2002</year>;<volume>28</volume>:<fpage>491</fpage>-<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr25-1090820X13493638">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinsapir</surname><given-names>KD</given-names></name>
<name><surname>Steinsapir</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Deep-fill hyaluronic acid for the temporary treatment of the naso-jugal groove: a report of 303 consecutive treatments</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2006</year>;<volume>22</volume>:<fpage>344</fpage>-<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr26-1090820X13493638">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gladstone</surname><given-names>HB</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Adverse effects when injecting facial fillers</article-title>. <source>Semin Cutan Med Surg</source>. <year>2007</year>;<volume>26</volume>:<fpage>34</fpage>-<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr27-1090820X13493638">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schanz</surname><given-names>S</given-names></name>
<name><surname>Schippert</surname><given-names>W</given-names></name>
<name><surname>Ulmer</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Arterial embolization caused by injection of hyaluronic acid (Restylane)</article-title>. <source>Br J Dermatol</source>. <year>2002</year>;<volume>146</volume>:<fpage>928</fpage>-<lpage>929</lpage>.</citation>
</ref>
<ref id="bibr28-1090820X13493638">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bachmann</surname><given-names>F</given-names></name>
<name><surname>Erdmann</surname><given-names>R</given-names></name>
<name><surname>Hartmann</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1629</fpage>-<lpage>1634</lpage>.</citation>
</ref>
<ref id="bibr29-1090820X13493638">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanke</surname><given-names>CW</given-names></name>
<name><surname>Higley</surname><given-names>HR</given-names></name>
<name><surname>Jolivette</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant</article-title>. <source>J Am Acad Dermatol</source>. <year>1991</year>;<volume>25</volume>:<fpage>319</fpage>-<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr30-1090820X13493638">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nettar</surname><given-names>K</given-names></name>
<name><surname>Maas</surname><given-names>C</given-names></name>
</person-group>. <article-title>Facial filler and neurotoxin complications</article-title>. <source>Facial Plast Surg</source>. <year>2012</year>;<volume>28</volume>:<fpage>288</fpage>-<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr31-1090820X13493638">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kassir</surname><given-names>R</given-names></name>
<name><surname>Kolluru</surname><given-names>A</given-names></name>
<name><surname>Kassir</surname><given-names>M</given-names></name>
</person-group>. <article-title>Extensive necrosis after injection of hyaluronic acid filler: case report and review of the literature</article-title>. <source>J Cosmet Dermatol</source>. <year>2011</year>;<volume>10</volume>:<fpage>224</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr32-1090820X13493638">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Jewell</surname><given-names>M</given-names></name>
<name><surname>Rubin</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Clinical conference: management of rare events following dermal fillers—focal necrosis and angry red bumps</article-title>. <source>Dermatol Surg</source>. <year>2006</year>;<volume>32</volume>:<fpage>426</fpage>-<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr33-1090820X13493638">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowe</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Arterial embolization caused by injection of hyaluronic acid (Restylane)</article-title>. <source>Br J Dermatol</source>. <year>2003</year>;<volume>148</volume>:<fpage>379</fpage>-<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr34-1090820X13493638">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castillo</surname><given-names>GD</given-names></name>
</person-group>. <article-title>Management of blindness in the practice of cosmetic surgery</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>1989</year>;<volume>100</volume>:<fpage>559</fpage>-<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr35-1090820X13493638">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peter</surname><given-names>S</given-names></name>
<name><surname>Mennel</surname><given-names>S</given-names></name>
</person-group>. <article-title>Retinal branch artery occlusion following injection of hyaluronic acid (Restylane)</article-title>. <source>Clin Experiment Ophthalmol</source>. <year>2006</year>;<volume>34</volume>:<fpage>363</fpage>-<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr36-1090820X13493638">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Apte</surname><given-names>RS</given-names></name>
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>Gehlbach</surname><given-names>P</given-names></name>
</person-group>. <article-title>Acute choroidal infarction following subcutaneous injection of micronized dermal matrix in the forehead region</article-title>. <source>Retina</source>. <year>2003</year>;<volume>23</volume>:<fpage>552</fpage>-<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr37-1090820X13493638">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>SS</given-names></name>
<name><surname>Song</surname><given-names>WK</given-names></name><etal/>
</person-group>. <article-title>Ocular ischemia with hypotony after injection of hyaluronic acid gel</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2011</year>;<volume>27</volume>:<fpage>e152</fpage>-<lpage>e155</lpage>.</citation>
</ref>
<ref id="bibr38-1090820X13493638">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kubota</surname><given-names>T</given-names></name>
<name><surname>Hirose</surname><given-names>H</given-names></name>
</person-group>. <article-title>Permanent loss of vision following cosmetic rhinoplastic surgery</article-title>. <source>Jpn J Ophthalmol</source>. <year>2005</year>;<volume>49</volume>:<fpage>535</fpage>-<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr39-1090820X13493638">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>SA</given-names></name>
<name><surname>Arthurs</surname><given-names>BP</given-names></name>
</person-group>. <article-title>Severe visual loss and orbital infarction following periorbital aesthetic poly-(L)-lactic acid (PLLA) injection</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2012</year>;<volume>28</volume>:<fpage>e68</fpage>-<lpage>e70</lpage>.</citation>
</ref>
<ref id="bibr40-1090820X13493638">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silva</surname><given-names>MT</given-names></name>
<name><surname>Curi</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Blindness and total ophthalmoplegia after aesthetic polymethylmethacrylate injection: case report</article-title>. <source>Arq Neuropsiquiatr</source>. <year>2004</year>;<volume>62</volume>:<fpage>873</fpage>-<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr41-1090820X13493638">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sung</surname><given-names>MS</given-names></name>
<name><surname>Kim</surname><given-names>HG</given-names></name>
<name><surname>Woo</surname><given-names>KI</given-names></name><etal/>
</person-group>. <article-title>Ocular ischemia and ischemic oculomotor nerve palsy after vascular embolization of injectable calcium hydroxylapatite filler</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2010</year>;<volume>26</volume>:<fpage>289</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr42-1090820X13493638">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>DY</given-names></name>
<name><surname>Park</surname><given-names>MH</given-names></name>
<name><surname>Koh</surname><given-names>SB</given-names></name><etal/>
</person-group>. <article-title>Multiple arterial embolism after illicit intranasal injection of collagenous material</article-title>. <source>Dermatol Surg</source>. <year>2010</year>;<volume>36</volume>:<fpage>1196</fpage>-<lpage>1199</lpage>.</citation>
</ref>
<ref id="bibr43-1090820X13493638">
<label>43.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hanke</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Adverse reactions to bovine collagen</article-title>. In: <person-group person-group-type="editor">
<name><surname>Klein</surname><given-names>AW</given-names></name>
</person-group>, ed. <source>Soft Tissue Augmentation in Clinical Practice: Procedures and Techniques</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Marcel Dekker</publisher-name>; <volume>1998</volume>:<fpage>145</fpage>.</citation>
</ref>
<ref id="bibr44-1090820X13493638">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Busso</surname><given-names>M</given-names></name>
<name><surname>McClaren</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S112</fpage>-<lpage>S121</lpage>.</citation>
</ref>
<ref id="bibr45-1090820X13493638">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindqvist</surname><given-names>C</given-names></name>
<name><surname>Tveten</surname><given-names>S</given-names></name>
<name><surname>Bondevik</surname><given-names>BE</given-names></name><etal/>
</person-group>. <article-title>A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds</article-title>. <source>Plast Reconstr Surg</source>. <year>2005</year>;<volume>115</volume>:<fpage>282</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr46-1090820X13493638">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sclafani</surname><given-names>AP</given-names></name>
<name><surname>Romo</surname><given-names>T</given-names><suffix>III</suffix></name>
<name><surname>Parker</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Homologous collagen dispersion (Dermalogen) as a dermal filler: persistence and histology compared with bovine collagen</article-title>. <source>Ann Plast Surg</source>. <year>2002</year>;<volume>49</volume>:<fpage>181</fpage>-<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr47-1090820X13493638">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Brandt</surname><given-names>F</given-names></name>
<name><surname>Leyden</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds</article-title>. <source>Dermatol Surg</source>. <year>2003</year>;<volume>29</volume>:<fpage>588</fpage>-<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr48-1090820X13493638">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carruthers</surname><given-names>A</given-names></name>
<name><surname>Carruthers</surname><given-names>J</given-names></name>
</person-group>. <article-title>Non-animal-based hyaluronic acid fillers: scientific and technical considerations</article-title>. <source>Plast Reconstr Surg</source>. <year>2007</year>;<volume>120</volume>:<fpage>33S</fpage>-<lpage>40S</lpage>.</citation>
</ref>
<ref id="bibr49-1090820X13493638">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Dayan</surname><given-names>SH</given-names></name>
<name><surname>Brandt</surname><given-names>FS</given-names></name><etal/>
</person-group>. <article-title>Persistence and improvement of nasolabial fold correction with nonanimal-stabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S2</fpage>-<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr50-1090820X13493638">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>SR</given-names></name>
<name><surname>Jones</surname><given-names>D</given-names></name>
<name><surname>Thomas</surname><given-names>JA</given-names></name><etal/>
</person-group>. <article-title>Duration of wrinkle correction following repeat treatment with Juvederm hyaluronic acid fillers</article-title>. <source>Arch Dermatol Res</source>. <year>2010</year>;<volume>302</volume>:<fpage>757</fpage>-<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr51-1090820X13493638">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Coleman</surname></name>
<name><surname>Donofrio</surname><given-names>LM</given-names></name><etal/>
</person-group>. <article-title>Improvement in nasolabial folds with a hyaluronic acid filler using a cohesive polydensified matrix technology: results from an 18-month open-label extension trial</article-title>. <source>Dermatol Surg</source>. <year>2010</year>;<volume>36</volume>(<supplement>suppl 3</supplement>):<fpage>1800</fpage>-<lpage>1808</lpage>.</citation>
</ref>
<ref id="bibr52-1090820X13493638">
<label>52.</label>
<citation citation-type="gov">
<collab>US Food and Drug Administration</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4391b1-01%20-%20FDA%20Executive%20Summary%20Dermal%20Fillers.pdf">http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4391b1-01%20-%20FDA%20Executive%20Summary%20Dermal%20Fillers.pdf</ext-link>. <access-date>Accessed October 10, 2012</access-date>.</citation>
</ref>
<ref id="bibr53-1090820X13493638">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Boulle</surname><given-names>K</given-names></name>
</person-group>. <article-title>Management of complications after implantation of fillers</article-title>. <source>J Cosmet Dermatol</source>. <year>2004</year>;<volume>3</volume>:<fpage>2</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr54-1090820X13493638">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>D</given-names></name>
</person-group>. <article-title>Volumizing the face with soft tissue fillers</article-title>. <source>Clin Plast Surg</source>. <year>2011</year>;<volume>38</volume>:<fpage>379</fpage>-<lpage>390</lpage>, <fpage>v</fpage>.</citation>
</ref>
<ref id="bibr55-1090820X13493638">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rohrich</surname><given-names>RJ</given-names></name>
<name><surname>Monheit</surname><given-names>G</given-names></name>
<name><surname>Nguyen</surname><given-names>AT</given-names></name><etal/>
</person-group>. <article-title>Soft-tissue filler complications: the important role of biofilms</article-title>. <source>Plast Reconstr Surg</source>. <year>2010</year>;<volume>125</volume>:<fpage>1250</fpage>-<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr56-1090820X13493638">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Rullan</surname><given-names>PP</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
</person-group>. <article-title>Avoiding and treating dermal filler complications</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>118</volume>:<fpage>92S</fpage>-<lpage>107S</lpage>.</citation>
</ref>
<ref id="bibr57-1090820X13493638">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Duffy</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Treatment options for dermal filler complications</article-title>. <source>Aesthetic Surg J</source>. <year>2006</year>;<volume>26</volume>:<fpage>356</fpage>-<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr58-1090820X13493638">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sclafani</surname><given-names>AP</given-names></name>
<name><surname>Fagien</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of injectable soft tissue filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1672</fpage>-<lpage>1680</lpage>.</citation>
</ref>
<ref id="bibr59-1090820X13493638">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Requena</surname><given-names>L</given-names></name>
<name><surname>Requena</surname><given-names>C</given-names></name>
<name><surname>Christensen</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions to injectable soft tissue fillers</article-title>. <source>J Am Acad Dermatol</source>. <year>2010</year>;<volume>64</volume>:<fpage>1</fpage>-<lpage>34</lpage>; quiz 35-36.</citation>
</ref>
<ref id="bibr60-1090820X13493638">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alam</surname><given-names>M</given-names></name>
<name><surname>Gladstone</surname><given-names>H</given-names></name>
<name><surname>Kramer</surname><given-names>EM</given-names></name><etal/>
</person-group>. <article-title>ASDS guidelines of care: injectable fillers</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S115</fpage>-<lpage>S148</lpage>.</citation>
</ref>
<ref id="bibr61-1090820X13493638">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wesley</surname><given-names>NO</given-names></name>
<name><surname>Dover</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The filler revolution: a six-year retrospective</article-title>. <source>J Drugs Dermatol</source>. <year>2009</year>;<volume>8</volume>:<fpage>903</fpage>-<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr62-1090820X13493638">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanchwala</surname><given-names>SK</given-names></name>
<name><surname>Holloway</surname><given-names>L</given-names></name>
<name><surname>Bucky</surname><given-names>LP</given-names></name>
</person-group>. <article-title>Reliable soft tissue augmentation: a clinical comparison of injectable soft-tissue fillers for facial-volume augmentation</article-title>. <source>Ann Plast Surg</source>. <year>2005</year>;<volume>55</volume>:<fpage>30</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr63-1090820X13493638">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leonhardt</surname><given-names>JM</given-names></name>
<name><surname>Lawrence</surname><given-names>N</given-names></name>
<name><surname>Narins</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Angioedema acute hypersensitivity reaction to injectable hyaluronic acid</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>577</fpage>-<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr64-1090820X13493638">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morley</surname><given-names>AM</given-names></name>
<name><surname>Malhotra</surname><given-names>R</given-names></name>
</person-group>. <article-title>Use of hyaluronic acid filler for tear-trough rejuvenation as an alternative to lower eyelid surgery</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2011</year>;<volume>27</volume>:<fpage>69</fpage>-<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr65-1090820X13493638">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alam</surname><given-names>M</given-names></name>
<name><surname>Dover</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Management of complications and sequelae with temporary injectable fillers</article-title>. <source>Plast Reconstr Surg</source>. <year>2007</year>;<volume>120</volume>:<fpage>98S</fpage>-<lpage>105S</lpage>.</citation>
</ref>
<ref id="bibr66-1090820X13493638">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graivier</surname><given-names>MH</given-names></name>
<name><surname>Bass</surname><given-names>LS</given-names></name>
<name><surname>Busso</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations</article-title>. <source>Plast Reconstr Surg</source>. <year>2007</year>;<volume>120</volume>:<fpage>55S</fpage>-<lpage>66S</lpage>.</citation>
</ref>
<ref id="bibr67-1090820X13493638">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Understanding, avoiding, and managing dermal filler complications</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S92</fpage>-<lpage>S99</lpage>.</citation>
</ref>
<ref id="bibr68-1090820X13493638">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beer</surname><given-names>KR</given-names></name>
</person-group>. <article-title>Radiesse nodule of the lips from a distant injection site: report of a case and consideration of etiology and management</article-title>. <source>J Drugs Dermatol</source>. <year>2007</year>;<volume>6</volume>:<fpage>846</fpage>-<lpage>847</lpage>.</citation>
</ref>
<ref id="bibr69-1090820X13493638">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sadick</surname><given-names>NS</given-names></name>
<name><surname>Katz</surname><given-names>BE</given-names></name>
<name><surname>Roy</surname><given-names>D</given-names></name>
</person-group>. <article-title>A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S122</fpage>-<lpage>S127</lpage>.</citation>
</ref>
<ref id="bibr70-1090820X13493638">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berlin</surname><given-names>A</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
<name><surname>Goldberg</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Calcium hydroxylapatite for facial rejuvenation</article-title>. <source>Semin Cutan Med Surg</source>. <year>2006</year>;<volume>25</volume>:<fpage>132</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr71-1090820X13493638">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>L</given-names></name>
<name><surname>Breiting</surname><given-names>V</given-names></name>
<name><surname>Janssen</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions to injectable soft tissue permanent fillers</article-title>. <source>Aesthetic Plast Surg</source>. <year>2005</year>;<volume>29</volume>:<fpage>34</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr72-1090820X13493638">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
<name><surname>Wolters</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Foreign body granulomas after all injectable dermal fillers, part 1: possible causes</article-title>. <source>Plast Reconstr Surg</source>. <year>2009</year>;<volume>123</volume>:<fpage>1842</fpage>-<lpage>1863</lpage>.</citation>
</ref>
<ref id="bibr73-1090820X13493638">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bentkover</surname><given-names>SH</given-names></name>
</person-group>. <article-title>The biology of facial fillers</article-title>. <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>73</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr74-1090820X13493638">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bailey</surname><given-names>SH</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
<name><surname>Kenkel</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Etiology, prevention, and treatment of dermal filler complications</article-title>. <source>Aesthetic Surg J</source>. <year>2011</year>;<volume>31</volume>:<fpage>110</fpage>-<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr75-1090820X13493638">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dayan</surname><given-names>SH</given-names></name>
<name><surname>Arkins</surname><given-names>JP</given-names></name>
<name><surname>Brindise</surname><given-names>R</given-names></name>
</person-group>. <article-title>Soft tissue fillers and biofilms</article-title>. <source>Facial Plast Surg</source>. <year>2011</year>;<volume>27</volume>:<fpage>23</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr76-1090820X13493638">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Coleman</surname><given-names>WP</given-names><suffix>III</suffix></name>
<name><surname>Glogau</surname><given-names>RG</given-names></name>
</person-group>. <article-title>Recommendations and treatment options for nodules and other filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1667</fpage>-<lpage>1671</lpage>.</citation>
</ref>
<ref id="bibr77-1090820X13493638">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bjarnsholt</surname><given-names>T</given-names></name>
<name><surname>Tolker-Nielsen</surname><given-names>T</given-names></name>
<name><surname>Givskov</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1620</fpage>-<lpage>1624</lpage>.</citation>
</ref>
<ref id="bibr78-1090820X13493638">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marusza</surname><given-names>W</given-names></name>
<name><surname>Mlynarczyk</surname><given-names>G</given-names></name>
<name><surname>Olszanski</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Probable biofilm formation in the cheek as a complication of soft tissue filler resulting from improper endodontic treatment of tooth 16</article-title>. <source>Int J Nanomedicine</source>. <year>2012</year>;<volume>7</volume>:<fpage>1441</fpage>-<lpage>1447</lpage>.</citation>
</ref>
<ref id="bibr79-1090820X13493638">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>L</given-names></name>
</person-group>. <article-title>Normal and pathologic tissue reactions to soft tissue gel fillers</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S168</fpage>-<lpage>S175</lpage>.</citation>
</ref>
<ref id="bibr80-1090820X13493638">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pecharki</surname><given-names>D</given-names></name>
<name><surname>Petersen</surname><given-names>FC</given-names></name>
<name><surname>Scheie</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Role of hyaluronidase in <italic>Streptococcus intermedius</italic> biofilm</article-title>. <source>Microbiology</source>. <year>2008</year>;<volume>154</volume>:<fpage>932</fpage>-<lpage>938</lpage>.</citation>
</ref>
<ref id="bibr81-1090820X13493638">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Attila</surname><given-names>C</given-names></name>
<name><surname>Ueda</surname><given-names>A</given-names></name>
<name><surname>Wood</surname><given-names>TK</given-names></name>
</person-group>. <article-title>5-Fluorouracil reduces biofilm formation in <italic>Escherichia coli</italic> K-12 through global regulator AriR as an antivirulence compound</article-title>. <source>Appl Microbiol Biotechnol</source>. <year>2009</year>;<volume>82</volume>:<fpage>525</fpage>-<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr82-1090820X13493638">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nyhlen</surname><given-names>A</given-names></name>
<name><surname>Ljungberg</surname><given-names>B</given-names></name>
<name><surname>Nilsson-Ehle</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Bactericidal effect of combinations of antibiotic and antineoplastic agents against <italic>Staphylococcus aureus</italic> and Escherichia coli</article-title>. <source>Chemotherapy</source>. <year>2002</year>;<volume>48</volume>:<fpage>71</fpage>-<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr83-1090820X13493638">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassuto</surname><given-names>D</given-names></name>
<name><surname>Marangoni</surname><given-names>O</given-names></name>
<name><surname>De Santis</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Advanced laser techniques for filler-induced complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1689</fpage>-<lpage>1695</lpage>.</citation>
</ref>
<ref id="bibr84-1090820X13493638">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moskowitz</surname><given-names>SM</given-names></name>
<name><surname>Foster</surname><given-names>JM</given-names></name>
<name><surname>Emerson</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Clinically feasible biofilm susceptibility assay for isolates of <italic>Pseudomonas aeruginosa</italic> from patients with cystic fibrosis</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>:<fpage>1915</fpage>-<lpage>1922</lpage>.</citation>
</ref>
<ref id="bibr85-1090820X13493638">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arron</surname><given-names>ST</given-names></name>
<name><surname>Neuhaus</surname><given-names>IM</given-names></name>
</person-group>. <article-title>Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid</article-title>. <source>J Cosmet Dermatol</source>. <year>2007</year>;<volume>6</volume>:<fpage>167</fpage>-<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr86-1090820X13493638">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazzeri</surname><given-names>D</given-names></name>
<name><surname>Agostini</surname><given-names>T</given-names></name>
<name><surname>Figus</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Blindness following cosmetic injections of the face</article-title>. <source>Plast Reconstr Surg</source>. <year>2012</year>;<volume>129</volume>:<fpage>995</fpage>-<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr87-1090820X13493638">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glaich</surname><given-names>AS</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
<name><surname>Goldberg</surname><given-names>LH</given-names></name>
</person-group>. <article-title>Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers</article-title>. <source>Dermatol Surg</source>. <year>2006</year>;<volume>32</volume>:<fpage>276</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr88-1090820X13493638">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Utilizing blunt-tipped cannulas in specific regions for soft-tissue augmentation</article-title>. <source>J Drugs Dermatol</source>. <year>2012</year>;<volume>11</volume>:<fpage>40</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr89-1090820X13493638">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hexsel</surname><given-names>D</given-names></name>
<name><surname>Soirefmann</surname><given-names>M</given-names></name>
<name><surname>Porto</surname><given-names>MD</given-names></name><etal/>
</person-group>. <article-title>Double-blind, randomized, controlled clinical trial to compare safety and efficacy of a metallic cannula with that of a standard needle for soft tissue augmentation of the nasolabial folds</article-title>. <source>Dermatol Surg</source>. <year>2012</year>;<volume>38</volume>:<fpage>207</fpage>-<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr90-1090820X13493638">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassuto</surname><given-names>D</given-names></name>
</person-group>. <article-title>Blunt-tipped microcannulas for filler injection: an ethical duty?</article-title> <source>J Drugs Dermatol</source>. <year>2012</year>;<volume>11</volume>:<fpage>41</fpage>.</citation>
</ref>
<ref id="bibr91-1090820X13493638">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Avoidance of arterial occlusion from injection of soft tissue fillers</article-title>. <source>Aesthetic Surg J</source>. <year>2002</year>;<volume>22</volume>:<fpage>555</fpage>-<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr92-1090820X13493638">
<label>92.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Duker</surname><given-names>J</given-names></name>
</person-group>. <article-title>Retinal arterial obstruction</article-title>. In: <person-group person-group-type="editor">
<name><surname>Yanoff</surname><given-names>M</given-names></name>
<name><surname>Duker</surname><given-names>JS</given-names></name>
</person-group>, eds. <source>Ophthalmology</source>. <edition>2nd ed</edition>. <publisher-loc>St Louis, MO</publisher-loc>: <publisher-name>Mosby</publisher-name>; <volume>2004</volume>:<fpage>854</fpage>-<lpage>861</lpage>.</citation>
</ref>
<ref id="bibr93-1090820X13493638">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schumacher</surname><given-names>M</given-names></name>
<name><surname>Schmidt</surname><given-names>D</given-names></name>
<name><surname>Jurklies</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial</article-title>. <source>Ophthalmology</source>. <year>2010</year>;<volume>117</volume>:<fpage>1367</fpage>-<lpage>1375</lpage>.e1.</citation>
</ref>
<ref id="bibr94-1090820X13493638">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>DH</given-names></name>
<name><surname>Yang</surname><given-names>HN</given-names></name>
<name><surname>Kim</surname><given-names>JC</given-names></name><etal/>
</person-group>. <article-title>Sudden unilateral visual loss and brain infarction after autologous fat injection into nasolabial groove</article-title>. <source>Br J Ophthalmol</source>. <year>1996</year>;<volume>80</volume>:<fpage>1026</fpage>-<lpage>1027</lpage>.</citation>
</ref>
<ref id="bibr95-1090820X13493638">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>SJ</given-names></name>
<name><surname>Woo</surname><given-names>SJ</given-names></name>
<name><surname>Park</surname><given-names>KH</given-names></name><etal/>
</person-group>. <article-title>Partial recovery after intraarterial pharmacomechanical thrombolysis in ophthalmic artery occlusion following nasal autologous fat injection</article-title>. <source>J Vasc Interv Radiol</source>. <year>2011</year>;<volume>22</volume>:<fpage>251</fpage>-<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr96-1090820X13493638">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shin</surname><given-names>H</given-names></name>
<name><surname>Lemke</surname><given-names>BN</given-names></name>
<name><surname>Stevens</surname><given-names>TS</given-names></name><etal/>
</person-group>. <article-title>Posterior ciliary-artery occlusion after subcutaneous silicone-oil injection</article-title>. <source>Ann Ophthalmol</source>. <year>1988</year>;<volume>20</volume>:<fpage>342</fpage>-<lpage>344</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>